NCCN Guidelines Version 2.2020
Distress Management

Rev. George F. Handzo, MA, MDiv £
Consultant
Laura Hoofring, MSN, APRN # θ †
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chao-Hui Huang, PhD θ
O'Neal Comprehensive Cancer Center at UAB
Pallavi Kumar, MD, MPH † £
Abramson Cancer Center at the University of Pennsylvania
Robin Lally, PhD, MS, RN #
Fred & Pamela Buffett Cancer Center
Sara Martin, MD £
Vanderbilt-Ingram Cancer Center
Lisa McGuffey, PhD, JD θ
University of Wisconsin Carbone Cancer Center
William Mitchell, MD † £
UC San Diego Moores Cancer Center
Laura J. Morrison, MD £
Yale Cancer Center/Smilow Cancer Hospital
Shehzad K. Niazi, MD θ
Mayo Clinic Cancer Center
Megan Pailler, PhD θ
Roswell Park Comprehensive Cancer Center
Oxana Palesh, PhD, MPH £
Stanford Cancer Institute
Francine Parnes, JD, MA ¥
Patient Advocate

Janice P. Pazar, RN, PhD θ £
St. Jude Children's Research Hospital/
The University of Tennessee Health Science Center
Laurel Ralston, DO θ
Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
Jaroslava Salman, MD θ
City of Hope National Medical Center
Moreen M. Shannon-Dudley, MSW £
Fred Hutchinson Cancer Research Center/ Seattle Cancer Care Alliance
Alan D. Valentine, MD θ
The University of Texas MD Anderson Cancer Center
Jessica Vanderlan, PhD θ
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

*Michelle B. Riba, MD, MS/Chair θ
University of Michigan Rogel Cancer Center
*Kristine A. Donovan, PhD, MBA/Vice-Chair θ
Moffitt Cancer Center
Barbara Andersen, PhD θ
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Ilana Braun, MD θ
Dana-Farber/Brigham and Women's Cancer Center
William S. Breitbart, MD θ † £
Memorial Sloan Kettering Cancer Center
Benjamin W. Brewer, PsyD θ
University of Colorado Cancer Center
Luke O. Buchmann, MD ¶
Huntsman Cancer Institute at the University of Utah
Molly Collins, MD £
Fox Chase Cancer Center
Cheyenne Corbett, PhD θ
Duke Cancer Institute
Stewart Fleishman, MD £ θ
Consultant
Sofia Garcia, PhD θ
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Donna B. Greenberg, MD θ † £
Dana-Farber/Brigham and Women's Cancer Center| Massachusetts General Hospital Cancer Center

NCCN Guidelines Panel Disclosures

ξ Bone marrow transplantation
Þ Internal medicine
† Medical oncology
# Nursing
¥ Patient advocacy
θ Psychiatry, psychology, including health behavior
* Discussion/Surgical oncology
 £ Supportive care including palliative, pain management, pastoral care, and oncology social work
£ £ Supportive care including palliative, pain management, pastoral care, and oncology social work

NCCN Distress Management Panel Members

Summary of the Guidelines Updates

Key Terms:
• Distress and Definition of Distress in Cancer (DIS-1)
• Standards of Care for Distress Management (DIS-2)

Overview of Evaluation and Treatment Process (DIS-3)
Management of Expected Distress Symptoms (DIS-4)

NCCN Distress Thermometer and Problem List (DIS-A)
Psychosocial Distress Patient Characteristics (DIS-B)

Psychological/Psychiatric Treatment Guidelines (DIS-5)
Social Work and Counseling Services: Practical Problems (DIS-23)
Social Work and Counseling Services: Psychosocial Problems (DIS-24)
Chaplaincy Care (DIS-25)
Principles for Implementation of Standards and Distress Management Guidelines (DIS-26)
Institutional Evaluation of Standards of Care (DIS-27)

For Non-Pain Symptom Management and Palliative Issues, See the NCCN Guidelines for Palliative Care
For Cancer Pain, See the NCCN Guidelines for Adult Cancer Pain

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/member_institutions.aspx.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See NCCN Categories of Evidence and Consensus.

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2020.
Updates in Version 2.2020 of the NCCN Guidelines for Distress Management from Version 1.2020 include:

**MS-1**
The Discussion section has been updated to reflect the changes in the algorithm.

Updates in Version 1.2020 of the NCCN Guidelines for Distress Management from Version 3.2019 include:

**Global**
- Term revised throughout algorithm: social work and counseling services

**DIS-1**
- Definition of Distress in Cancer has been moved to this page
- Definition of Distress was revised: "...that may interfere with the one’s ability to cope effectively with cancer..."

**DIS-A**
- Definition of Distress was added to this page
- Food was added to the Problem List

**DIS-B**
- Sub-bullets added to Social issues:
  - Immigration
  - Loss of stable housing/shelter/living environment
  - Current substance use
- Footnote removed: From the NCCN Guidelines for Palliative Care

**DIS-5**
- Bullet 2 revised: Problematic behaviors Behavioral changes
- Bullet added: Problems in relationships
- Bullet 10 revised: Impaired cognitive capacity function

**DIS-9**
- Depressive Disorders: Signs and symptoms of depressive the following disorders in cancer including
- Treatment

- Bullet added here and on DIS-11 for no danger to self and others: Consider online or telehealth resources
- Bullet added here, DIS-11, and DIS-17 for danger to self and others: Safety planning

**DIS-13**
- Schizophrenia Spectrum and Other Psychotic Disorders: Signs and symptoms of psychotic episode in during cancer care/treatment or history of schizophrenia/psychotic disorder

**DIS-14**
- Under Treatment, bullet added here, DIS-19, and DIS-22: Consider referral to psychiatry

**DIS-15**
- Anxiety Disorders: Signs and symptoms of anxiety disorder in cancer the following disorders
- Bullet added: Social anxiety disorder
- Evaluation
  - Separated into two bullets here and on DIS-16: Anxiety or Panic attacks

**DIS-16**
- Trauma and Stressor-Related Disorders: Signs and symptoms of trauma and stressor-related the following disorders in cancer
- Sub-bullets added to Evaluation:
  - Intrusions
  - Avoidance
  - Dissociation

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Updates in Version 1.2020 of the NCCN Guidelines for Distress Management from Version 3.2019 include:

**DIS-19**
- Sub-bullet added to Evaluation: Presence of obsessions or compulsions

**DIS-20**
- Signs, symptoms, and history of dependence active substance use disorder or addiction
- Sub-bullets added under Evaluation
  - Assess safety concerns
  - Assess decision-making ability
  - Evaluate family and home environment
- Bullet revised: Current substance use disorder (illegal and legal including cannabis, prescription opioids, caffeine, and supplements)
  - Bullet revised: Current substance use disorder (illegal and legal including cannabis, prescription opioids, caffeine, and supplements)
- Bullet added under Treatment: Evaluate for intoxication and withdrawal risk

**DIS-22**
- Sub-bullet revised under Evaluation: Withdrawal states syndromes

**DIS-23**
- Referral by oncology team to social work and counseling services, case management, or patient navigation

**DIS-25**
- Bullet added under Chaplaincy Assessment: Dealing with issues of forgiveness
“DISTRESS”

The term “distress” was chosen because it:

• Is more acceptable and less stigmatizing than “psychiatric,” “psychosocial,” or “emotional”

• Sounds “normal” and less embarrassing

• Can be defined and measured by self-report

DEFINITION OF DISTRESS IN CANCER

Distress is a multifactorial unpleasant experience of a psychological (ie, cognitive, behavioral, emotional), social, spiritual, and/or physical nature that may interfere with one’s ability to cope effectively with cancer, its physical symptoms, and its treatment. Distress extends along a continuum, ranging from common normal feelings of vulnerability, sadness, and fears to problems that can become disabling, such as depression, anxiety, panic, social isolation, and existential and spiritual crisis.
STANDARDS OF CARE FOR DISTRESS MANAGEMENT

• Distress should be recognized, monitored, documented, and treated promptly at all stages of disease and in all settings.

• Screening should identify the level and nature of the distress.

• Ideally, patients should be screened for distress at every medical visit as a hallmark of patient-centered care. At a minimum, patients should be screened for distress at their initial visit, at appropriate intervals, and as clinically indicated, especially with changes in disease status (ie, remission, recurrence, progression, treatment-related complications).

• Distress should be assessed and managed according to clinical practice guidelines.

• Interdisciplinary institutional committees should be formed to implement standards for distress management.

• Educational and training programs should be developed to ensure that health care professionals and certified chaplains have knowledge and skills in the assessment and management of distress.

• Licensed mental health professionals and certified chaplains experienced in psychosocial aspects of cancer should be readily available as staff members or by referral.

• Medical care contracts should include adequate reimbursement for services provided by mental health professionals.

• Clinical health outcomes measurement should include assessment of the psychosocial domain (eg, quality of life and patient and family satisfaction).

• Patients, families, and treatment teams should be informed that distress management is an integral part of total medical care and is provided with appropriate information about psychosocial services in the treatment center and the community.

• Quality of distress management programs/services should be included in institutional continuous quality improvement (CQI) projects.
OVERVIEW OF EVALUATION AND TREATMENT PROCESS

**EVALUATION**

- Clinical evidence of moderate to severe distress or score of 4 or more on screening tool (DIS-A)
- Unrelieved physical symptoms, treat as per disease-specific or supportive care guidelines
- Clinical evidence of mild distress or score of less than 4 on screening tool (DIS-A)

**TREATMENT**

- Mental health professional
- Social work and counseling services
- Chaplaincy care
- Primary oncology team + resources available

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

**Clinical evidence of moderate to severe distress or score of 4 or more on screening tool (DIS-A)**

- Unrelieved physical symptoms, treat as per disease-specific or supportive care guidelines

**Clinical evidence of mild distress or score of less than 4 on screening tool (DIS-A)**

- Clinical assessment (which may include clinical interviews, and validated scales/screeners for anxiety and depression) by primary oncology team of oncologist, nurse, advanced practice professional, and social worker for:
  - High-risk patients
  - Periods of vulnerability
  - Risk factors for distress
  - Practical problems
  - Family problems
  - Spiritual/religious concerns
  - Physical problems
  - Social problems
  - Emotional problems, including anxiety and depression

Referral

- If necessary

**Brief screening for distress (DIS-A):**

- Screening tool
- Problem list

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**a** The Problem List of the NCCN Distress Thermometer Screening Tool may be modified to fit the needs of the local population.

**b** See Discussion (MS-8) for information about other validated screening tools.

**c** Consider referral for palliative care management (See NCCN Guidelines for Palliative Care and NCCN Guidelines for Adult Cancer Pain).

**d** See Psychosocial Distress Patient Characteristics (DIS-B).

**e** Psychiatrist, psychologist, advanced practice clinicians, and/or social worker.

Refer to NCCN Guidelines Table of Contents for Supportive Care Guidelines

---

DIS-3
# Management of Expected Distress Symptoms

<table>
<thead>
<tr>
<th>Expected Distress Symptoms</th>
<th>Interventions</th>
<th>Re-evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fear and worry about the future</td>
<td>Acknowledge/validate distress</td>
<td>Stable or diminished distress</td>
</tr>
<tr>
<td>Concerns about illness</td>
<td>Clarify diagnosis, treatment options, and side effects</td>
<td>Continue monitoring and support</td>
</tr>
<tr>
<td>Sadness about loss of usual health</td>
<td>Be sure patient understands disease and treatment options</td>
<td></td>
</tr>
<tr>
<td>Anger, feeling out of control</td>
<td>Discuss advance care planning</td>
<td></td>
</tr>
<tr>
<td>Poor sleep</td>
<td>Refer to appropriate patient education materials (eg, NCCN Guidelines for Patients)</td>
<td></td>
</tr>
<tr>
<td>Poor appetite</td>
<td>Educate patient that points of transition may bring increased vulnerability to distress</td>
<td></td>
</tr>
<tr>
<td>Poor concentration</td>
<td>Ensure continuity of care</td>
<td></td>
</tr>
<tr>
<td>Preoccupation with thoughts of illness and death</td>
<td>Mobilize resources</td>
<td></td>
</tr>
<tr>
<td>Concerns with disease or treatment side effects</td>
<td>Consider medication to manage symptoms:</td>
<td></td>
</tr>
<tr>
<td>Concerns about social role (ie, as father, mother)</td>
<td>Analgesics (See NCCN Guidelines for Adult Cancer Pain)</td>
<td>Monitor functional level and reevaluate as appropriate</td>
</tr>
<tr>
<td>Spiritual/existential concerns</td>
<td>Anxiolytics</td>
<td></td>
</tr>
<tr>
<td>Financial worries</td>
<td>Hypnotics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Antidepressants</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Psychostimulants</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Support groups and/or individual counseling</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Family/couple/caregiver support and counseling</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Relaxation, meditation, creative therapies (eg, art, dance, music)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Spiritual support</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Exercise</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assess and strengthen coping strategies</td>
<td></td>
</tr>
</tbody>
</table>

---

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

See Psychosocial Distress Patient Characteristics (DIS-B).
NCCN DISTRESS THERMOMETER
Distress is an unpleasant experience of a mental, physical, social, or spiritual nature. It can affect the way you think, feel, or act. Distress may make it harder to cope with having cancer, its symptoms, or its treatment.

Instructions: Please circle the number (0–10) that best describes how much distress you have been experiencing in the past week including today.

Extreme distress

No distress

**PROBLEM LIST**
Please indicate if any of the following has been a problem for you in the past week including today. Be sure to check YES or NO for each.

---

**Practical Problems**
- Child care
- Food
- Housing
- Insurance/financial
- Transportation
- Work/school
- Treatment decisions

**Family Problems**
- Dealing with children
- Dealing with partner
- Ability to have children
- Family health issues

**Emotional Problems**
- Depression
- Fears
- Nervousness
- Sadness
- Worry
- Loss of interest in usual activities

**Spiritual/religious concerns**

**Physical Problems**
- Appearance
- Bathing/dressing
- Breathing
- Changes in urination
- Constipation
- Diarrhea
- Eating
- Fatigue
- Feeling swollen
- Fevers
- Getting around
- Indigestion
- Memory/concentration
- Mouth sores
- Nausea
- Nose dry/congested
- Pain
- Sexual
- Skin dry/itchy
- Sleep
- Substance use
- Tingling in hands/feet

Other Problems: __________________________
### PSYCHOSOCIAL DISTRESS PATIENT CHARACTERISTICS

<table>
<thead>
<tr>
<th>PATIENTS AT INCREASED RISK FOR DISTRESS</th>
<th>PERIODS OF INCREASED VULNERABILITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>• History of psychiatric disorder or substance use disorder</td>
<td>• Finding and investigating a suspicious symptom</td>
</tr>
<tr>
<td>• History of depression/suicide attempt</td>
<td>• During diagnostic workup</td>
</tr>
<tr>
<td>• History of trauma and/or abuse (physical, sexual, emotional, verbal)</td>
<td>• Finding out the diagnosis</td>
</tr>
<tr>
<td>• Cognitive impairment</td>
<td>• Advanced cancer diagnosis</td>
</tr>
<tr>
<td>• Communication barriers(^2)</td>
<td>• Learning about genetic/familial cancer risk</td>
</tr>
<tr>
<td>• Severe comorbid illnesses</td>
<td>• Awaiting treatment</td>
</tr>
</tbody>
</table>
| • Social issues:  
  ▶ Family/caregiver conflicts  
  ▶ Inadequate social support  
  ▶ Living alone  
  ▶ Financial problems  
  ▶ Limited access to medical care  
  ▶ Young or dependent children  
  ▶ Younger age\(^3\)  
  ▶ Immigration  
  ▶ Loss of stable housing/shelter/living environment  
  ▶ Current substance use  
  ▶ Other stressors  
  ▶ Spiritual/religious concerns  
  ▶ Uncontrolled symptoms  
  ▶ Cancer type associated with risk of depression (eg, pancreatic cancer, head and neck cancer) | • Increase in symptom burden  
• Significant treatment-related complication(s)  
• Admission to/discharge from hospital  
• Change in treatment modality  
• Treatment failure  
• End of active treatment  
• Medical follow-up and surveillance  
• Transition to survivorship  
• Recurrence/progression  
• Transition to end-of-life care |


\(^{2}\)Communication barriers include language, literacy, and physical barriers.

\(^{3}\)See NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology.
Evaluation for:
- Distress
- Behavioral changes
- Problems in relationships
- Psychiatric history/medications
- Substance use disorder
- Pain and symptom control
  - NCCN Guidelines for Adult Cancer Pain
  - NCCN Guidelines for Palliative Care
- Fatigue
  - (See NCCN Guidelines for Cancer-Related Fatigue)
- Body image
- Sexual health
  - (See NCCN Guidelines for Survivorship: Sexual Function, SSF-1)
- Impaired cognitive function
  - (See NCCN Guidelines for Survivorship: Cognitive Function, SCF-1)
- Safety
- Suicide risk
- Psychological/psychiatric disorder
- Medical causes
  - (refer to primary oncology team)

Referral by oncology team to mental health team e

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

Psychological/psychiatric treatment guidelines:

- Neurocognitive Disorders: Dementia (DIS-6)
- Neurocognitive Disorders: Delirium (DIS-8)
- Depressive Disorders (DIS-9)
- Bipolar and Related Disorders (DIS-11)
- Schizophrenia Spectrum and Other Psychotic Disorders (DIS-13)
- Anxiety Disorders (DIS-15)
- Trauma and Stressor-Related Disorders (DIS-16)
- Trauma and Stressor-Related Disorders: Adjustment Disorders (DIS-17)
- Obsessive Compulsive and Related Disorders (DIS-19)
- Substance-Related and Addictive Disorders (DIS-20)
- Personality Disorders (DIS-22)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Psychiatrist, psychologist, advanced practice clinicians, and/or social worker.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
NEUROCOGNITIVE DISORDERS (NCD):
DEMENTIA

Signs and symptoms of dementia in cancer

Neurologic/cognitive and mental status examination ± neuropsychological testing

| Impairment present | ||| Impairment |  Evaluate for
| ||| No impairment |  Evaluate for depression

Evaluate for
• NCD: Delirium
• NCD: Dementia
• Assess safety
• Assess capacity to make decisions

Decision-making capacity and safety impaired

Document and refer to institutional policies and procedures

Thought disorder/psychosis

Arrange for ongoing primary psychiatric management

Negative
Observe

Positive
See Depressive Disorders (DIS-9)

See NCD: Delirium (DIS-8)

See NCD: Dementia (DIS-7)

Return to Psychological/Psychiatric Treatment Guidelines (DIS-5)
• Evaluation, diagnostic studies, and modification of factors related to:
  ▶ Cancer
  ▶ Treatment
  ▶ Medications
  ▶ Medical causes
  ▶ Withdrawal states
  ▶ Pain, fatigue, sleep problems, and other symptoms
• Assess safety
• Assess family/caregiver resources

Cognitive rehabilitation ± medications

Response

No/partial response

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

• Reevaluate
• Attend to patient safety
• Consider capacity to make decisions
• Refer to social work and counseling services
• Consider alternate level of care

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

Return to Psychological/Psychiatric Treatment Guidelines (DIS-5)
Signs and symptoms of delirium in cancer

- Evaluation, diagnostic studies, and modification of factors related to:
  - Cancer
  - Treatment
  - Medications
  - Medical causes
  - Withdrawal states
  - Pain and other symptoms
- Assess safety
- Assess decision-making capacity

Behavioral management
+ family support/education environment ± pharmacotherapy

Response

No/partial response → Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

- Augment medication
- Continue:
  - Support
  - Education
  - Safety
- Assess decision-making capacity
- Re-evaluate cause of delirium

Response

No/partial response → Reevaluate

Consider NCD: Dementia → See (DIS-6)

Management of withdrawal states may vary depending upon the substance.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### DEPRESSIVE DISORDERS

**Signs and symptoms of the following disorders:**
- Depressive disorders related to medical illness
- Major depressive disorders
- Persistent depressive disorder

### EVALUATION

- Evaluation, diagnostic studies, and modification of factors related to:
  - Cancer
  - Treatment
  - Medications
  - Medical causes
  - Withdrawal states
  - Pain
  - Fatigue
  - Sleep disruption
  - Anorexia
  - Anhedonia
  - Decreased interest in activities
  - Wish to die
  - Suicidal thoughts
  - Mood swings
  - Poor concentration
  - Demoralization
- Consider psychosocial and spiritual concerns
- Assess decision-making capacity
- Assess safety
- Evaluate family/home environment
- Evaluate alcohol and recreational drug use
- Evaluate using PHQ-2 or PHQ-9

### TREATMENT

- Psychotherapy
- Psychotropic medication (category 1)
- Mental health treatment and follow-up/patient and family education
- Consider online or telehealth resources
- Consider referral to social work and counseling services or chaplaincy care [See Social Work and Counseling Services (DIS-23) or Chaplaincy Care (DIS-25)]

### FOLLOW-UP

- Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

#### No danger to self or others

- Mental health treatment and follow-up/patient and family education

#### Danger to self or others

- Evaluate suicide and homicide risk
- Consider hospitalization
- Assure patient safety:
  - Order psychiatric consultation
  - Increase monitoring
  - Safety planning
  - Remove guns/dangerous objects
- Assure safety of others
- Consider referral to social work and counseling services or chaplaincy care [See Social Work and Counseling Services (DIS-23) or Chaplaincy Care (DIS-25)]

#### Response

- Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

#### No/partial response

- See (DIS-10)

---

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
### DEPRESSIVE DISORDERS (continued)

<table>
<thead>
<tr>
<th>EVALUATION</th>
<th>TREATMENT</th>
<th>FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>No or partial response to treatment for signs and symptoms of depressive disorders in cancer</td>
<td>Reevaluate diagnosis and response/adjust medications as indicated ± psychotherapy</td>
<td>Follow-up and communication with primary oncology team, primary care physician, and family/caregivers</td>
</tr>
<tr>
<td>Response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No/partial response</td>
<td>• Consider augmenting or changing medications</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Consider electroconvulsive therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Consider consult/second opinion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Re-evaluate psychotherapeutic intervention and consider higher level care with intensive outpatient program</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Return to Psychological/Psychiatric Treatment Guidelines (DIS-5)
**BIPOLAR AND RELATED DISORDERS**

Signs and symptoms of the following disorders:
- Bipolar and related disorders due to medical illness
- Bipolar I and bipolar II
- Cyclothymic disorder

**EVALUATION**

- Evaluation, diagnostic studies, and modification of factors related to:
  - Cancer
  - Treatment
  - Medications
  - Evaluate medication adherence
  - Medical causes
  - Withdrawal states
  - Pain
  - Fatigue
  - Sleep disruption
  - Anorexia
  - Anhedonia
  - Decreased interest in activities
  - Wish to die
  - Suicidal thoughts
  - Mood swings
  - Consider psychosocial and spiritual concerns
  - Assess decision-making capacity
  - Assess safety
  - Evaluate family/home environment
  - Evaluate alcohol and recreational drug use

**TREATMENT**

- Psychotherapy
- Psychotropic medication (category 1)
- Mental health treatment and follow-up/patient and family education
- Consider online or telehealth resources
- Consider referral to social work and counseling services or chaplaincy care See Social Work and Counseling Services (DIS-23) or Chaplaincy Care (DIS-25)

**FOLLOW-UP**

- Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

- Response

- No/partial response

- Mental health treatment and follow-up/patient and family education

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
BIPOLAR AND RELATED DISORDERS (continued)

No or partial response to treatment for signs and symptoms of bipolar and related disorders in cancer

<table>
<thead>
<tr>
<th>EVALUATION</th>
<th>TREATMENT</th>
<th>FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reevaluate diagnosis and response/adjust medications as indicated ± psychotherapy</td>
<td>• Consider augmenting or changing medications   • Consider electroconvulsive therapy   • Consider consult/second opinion   • Re-evaluate psychotherapeutic intervention and consider higher level care with intensive outpatient program</td>
<td>Follow-up and communication with primary oncology team, primary care physician, and family/caregivers</td>
</tr>
</tbody>
</table>

Response

No/partial response

Return to Psychological/Psychiatric Treatment Guidelines (DIS-5)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS

EVALUATION

No active signs of psychosis

- Obtain history of psychosis/schizophrenia/affective psychosis
- Obtain history of medications/substances (such as corticosteroids)
- Neurologic and mental status examination

Psychotic signs on mental status examination (especially hallucination/delusion/thought disorder)

- Evaluate for:
  - NCD: Delirium
  - Corticosteroid-induced psychosis
  - Substance-related and addictive disorders
  - New diagnosis or relapse of psychotic disorder
  - Depressive disorders
  - Bipolar and related disorders
  - NCD: Dementia
  - Akathisia from antipsychotics or antiemetics
- Assess safety
- Assess capacity to make decisions
- Evaluate family/home environment

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

- NCD: Dementia
  - See DIS-6
- Depression
  - See DIS-8
- Bipolar and related disorders
  - See DIS-9
- Schizophrenia spectrum and other psychotic disorders
  - See DIS-14
- Substance-related disorder and addictive disorders
  - See DIS-20
- Decision-making capacity and safety impaired
- Document and refer to institutional policies and procedures

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
SCHIZOPHRENIA SPECTRUM AND OTHER PSYCHOTIC DISORDERS

(continued)

• Evaluation, diagnostic studies, and modification of factors related to:
  ▸ Cancer
  ▸ Treatment
  ▸ Medications (particularly steroids)
  ▸ NCD: Delirium
  ▸ NCD: Dementia
  ▸ Withdrawal states or substance use disorder
  ▸ New diagnosis of psychotic disorder
  ▸ Relapse of psychotic disorder (eg, not taking maintenance anti-psychotic medications)
  ◊ Evaluate medication adherence
• Assess safety
• Assess capacity to make decisions
• Assess family/caregiver resources including inpatient psychiatry hospitalization and community mental health team

<table>
<thead>
<tr>
<th>TREATMENT</th>
<th>FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Secure safety</td>
<td>Follow-up and communication with primary oncology team, primary care physician, and family/caregivers</td>
</tr>
<tr>
<td>• Consider anti-psychotic medications (urgently administer)</td>
<td></td>
</tr>
<tr>
<td>• Consider medications for mood</td>
<td></td>
</tr>
<tr>
<td>• Consider referral to psychiatry</td>
<td></td>
</tr>
<tr>
<td>• Consider transfer to psychiatric unit/hospital</td>
<td></td>
</tr>
<tr>
<td>• Consider role of electroconvulsive therapy in psychotic depression/mania, catatonia</td>
<td></td>
</tr>
</tbody>
</table>

Response

No/partial response

• Reevaluate
• Attend to patient safety
• Consider capacity to make decisions
• Maintain communication with team for chronic psychotic disorder/psychiatric service
• Consider alternate level of care

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
ANXIETY DISORDERS

- Anxiety due to general medical condition
- Generalized anxiety disorder
- Panic disorder
- Specific phobia
- Agoraphobia
- Social anxiety disorder
- Substance/medication-induced anxiety disorder
- Conditioned nausea/vomiting (See NCCN Guidelines for Antiemesis)

EVALUATION

- Evaluation, diagnostic studies, and modification of factors related to:
  - Cancer
  - Treatment
  - Nausea/vomiting
  - Medications
  - Medical causes
  - Withdrawal states
  - Pain
  - Poor concentration
  - Sleep disruption
  - Anxiety
  - Panic attacks
  - Hypervigilance
  - Fears
  - Irritability
- Assess safety
- Assess decision-making capacity
- Evaluate family and home environment
- Evaluate alcohol and recreational drug use
- Consider spiritual/religious concerns (see Chaplaincy Care DIS-25)

TREATMENT

- Psychotherapy (category 1) ± antidepressant ± anxiolytic

FOLLOW-UP

- Follow-up and communication with primary oncology team, primary care physician, and family/caregivers
- Reevaluate medication (consider antipsychotics), psychotherapy, support, education

Response

No/partial response

Response

No/partial response

Evaluate for depression and other psychiatric comorbidity

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
TRAUMA AND STRESSOR-RELATED DISORDERS

EVALUATION

- Evaluation, diagnostic studies, and modification of factors related to:
  - Cancer
  - Treatment
  - Medications
  - Medical causes
  - Pain
  - Poor concentration
  - Sleep disruption
  - Anxiety
  - Panic attacks
  - Hypervigilance
  - Intrusions
  - Avoidance
  - Dissociation
  - Fears
  - Irritability
- Assess safety
- Assess decision-making capacity
- Evaluate family and home environment
- Assess past trauma and/or cancer-related post-traumatic stress

TREATMENT

Psychotherapy (category 1)
- ± antidepressant
- ± anxiolytic

Response

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

FOLLOW-UP

Response

No/partial response

Reevaluate medication (consider antipsychotics, psychotherapy, support, education)

No/partial response

Evaluate for depression and other psychiatric comorbidity

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Return to Psychological/Psychiatric Treatment Guidelines (DIS-5)
TRAUMA AND STRESSOR-RELATED DISORDERS: ADJUSTMENT DISORDERS

Signs and symptoms of adjustment disorders in cancer (anxiety and/or depressive symptoms)

EVALUATION

Moderate/severe adjustment disorder

Mild adjustment disorder

No danger to self or others

Danger to self or others

TREATMENT

Medications and/or psychotherapy

Initiate psychotherapy/counseling

No/partial response

Response

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

FOLLOW-UP

• Adjust medications/dosages
• Re-evaluate psychotherapy, support, education

• Evaluate suicide and homicide risk
• Consider hospitalization
• Assure patient safety:
  ‣ Order psychiatric consultation
  ‣ Increase monitoring
  ‣ Safety planning
  ‣ Remove guns/dangerous objects
• Assure safety of others
• Consider referral to social work and counseling services or chaplaincy care

See Social Work and Counseling Services (DIS-23) or Chaplaincy Care (DIS-25)

Follow-up for hospitalized patients and outpatients

See Reevaluate mild adjustment (DIS-18)

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
TRAUMA AND STRESSOR-RELATED DISORDERS:
ADJUSTMENT DISORDERS
(continued)

Reevaluate patients with moderate/severe adjustment disorders after adjusting medications/dosages

Response

Another disorder without personality disorders

No/partial response

Personality disorders

Continue therapy
Reevaluate

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

See appropriate psychological/psychiatric pathway (DIS-5)

See Personality Disorders (DIS-22)

Response

Adjustment disorders

No/partial response

Another disorder without personality disorders

Personality disorders

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

See pathway for Moderate/severe adjustment disorder Medications and/or psychotherapy (DIS-17)

See appropriate psychological/psychiatric pathway (DIS-5)

See Personality Disorders (DIS-22)

Return to Psychological/Psychiatric Treatment Guidelines (DIS-5)
# OBSESSIVE COMPULSIVE AND RELATED DISORDERS

## EVALUATION

- Evaluation, diagnostic studies, and modification of factors related to:
  - Cancer
  - Treatment
  - Medications
  - Medical causes
  - Withdrawal states
  - Poor concentration
  - Sleep disruption
  - Presence of obsessions or compulsions
  - Anxiety
  - Panic attacks
  - Hypervigilance
  - Fears
  - Irritability
- Assess safety
- Assess decision-making capacity
- Evaluate family and home environment

## TREATMENT

- Psychotherapy (category 1) ± antidepressant ± anxiolytic
- Consider referral to psychiatry

## FOLLOW-UP

- Follow-up and communication with primary oncology team, primary care physician, and family/caregivers
- Reevaluate medication (consider antipsychotics), psychotherapy, support, education
- Evaluate for depression and other psychiatric comorbidity
- Response
- No/partial response

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**DIS-19**

---

Return to Psychological/Psychiatric Treatment Guidelines (DIS-5)
### SUBSTANCE-RELATED AND ADDICTIVE DISORDERS

<table>
<thead>
<tr>
<th>EVALUATION</th>
<th>TREATMENT</th>
</tr>
</thead>
</table>
| • Substance use disorder history  
• Toxicology screen  
• Labs, as clinically indicated  
• Assess impact on patient with respect to cancer treatment  
• Assess safety concerns  
• Assess decision-making ability  
• Evaluate family and home environment | • Evaluate for intoxication and withdrawal risk  
• Treat symptoms  
• Substance use disorder treatment program  
• Discuss risk reduction strategies |
| Current substance use disorder (illegal and legal including cannabis, prescription opioids, caffeine, and supplements) |  |
| History of substance use disorder |  |

### Notes
- Substance use disorder
- History of substance use disorder

9Opioids, alcohol, tobacco, or other. For opioids, also see Opioid Principles, Prescribing, Titration, Maintenance, and Safety in the NCCN Guidelines for Adult Cancer Pain (page PAIN-E). For tobacco use see the NCCN Guidelines for Smoking Cessation.

---

**DIS-20**

**NCCN Guidelines Index**

**Table of Contents**

**Discussion**
SUBSTANCE-RELATED AND ADDICTIVE DISORDERS (continued)

Following appropriate treatment and/or management program

Response

- Psychoeducation ± psychotherapy ± medications

Referral to specialized maintenance program or Discuss strategies for substance use disorder prevention

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

No/partial response

- Evaluate for active substance use disorder

- Treatment team meeting
- Reevaluate for other psychiatric comorbidity

See appropriate psychological/psychiatric pathway (DIS-5)

FOLLOW-UP

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Note: All recommendations are category 2A unless otherwise indicated.
### PERSONALITY DISORDERS

<table>
<thead>
<tr>
<th>Signs and symptoms of personality disorders in cancer:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Personality change related to medical or treatment factors</td>
</tr>
<tr>
<td>• Borderline</td>
</tr>
<tr>
<td>• Histrionic</td>
</tr>
<tr>
<td>• Schizoid</td>
</tr>
<tr>
<td>• Obsessive-compulsive</td>
</tr>
<tr>
<td>• Paranoid</td>
</tr>
<tr>
<td>• Antisocial</td>
</tr>
<tr>
<td>• Narcissistic</td>
</tr>
<tr>
<td>• Dependent</td>
</tr>
<tr>
<td>• Schizotypal</td>
</tr>
</tbody>
</table>

### EVALUATION

<table>
<thead>
<tr>
<th>Evaluation, diagnostic studies, and modification of factors related to:</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Cancer</td>
</tr>
<tr>
<td>• Treatment</td>
</tr>
<tr>
<td>• Medications</td>
</tr>
<tr>
<td>• Medical causes</td>
</tr>
<tr>
<td>• Withdrawal syndromes</td>
</tr>
<tr>
<td>• Pain</td>
</tr>
<tr>
<td>• Manipulative behavior</td>
</tr>
<tr>
<td>• Anger</td>
</tr>
<tr>
<td>• Threatening behavior</td>
</tr>
<tr>
<td>• Histrionic behavior</td>
</tr>
<tr>
<td>• Demanding behavior</td>
</tr>
<tr>
<td>• Fear</td>
</tr>
<tr>
<td>• Assess safety</td>
</tr>
<tr>
<td>• Assess decision-making capacity</td>
</tr>
<tr>
<td>• Assess home situation</td>
</tr>
</tbody>
</table>

### TREATMENT

<table>
<thead>
<tr>
<th>Develop coordinated behavioral, psychological, and medical treatment plan with health care team (behavioral management ± medications)</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Provide staff education for management</td>
</tr>
<tr>
<td>• Consider referral to psychiatry</td>
</tr>
</tbody>
</table>

### FOLLOW-UP

<table>
<thead>
<tr>
<th>Follow-up and communication with primary oncology team, primary care physician, and family/caregivers</th>
</tr>
</thead>
</table>

Response

<table>
<thead>
<tr>
<th>Reevaluate for other psychiatric comorbidity or substance use disorder</th>
</tr>
</thead>
</table>

No/partial response

---

hFor a complete list of personality disorders, see the American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Return to Psychological/Psychiatric Treatment Guidelines (DIS-5)
### Social Work and Counseling Services

<table>
<thead>
<tr>
<th>CATEGORY</th>
<th>TYPE OF PROBLEM</th>
<th>SOCIAL WORK AND COUNSELING INTERVENTIONS</th>
</tr>
</thead>
</table>
| **Practical problems** | • Illness-related problems  
• Basic needs, including housing, food, financial/insurance concerns, assistance with activities of daily living (ADLs), and transportation  
• Employment/school/career concerns  
• Cultural/language issues  
• Family and caregiver availability |  
  - Mild  
    - Patient/family education  
    - Education/support group sessions  
    - Resource lists  

| **Psychosocial problems** | See (DIS-24) |  
  - Severe/moderate  
    - Patient and family counseling/psychotherapy  
    - Community resource mobilization/linkage  
    - Problem-solving teaching  
    - Advocacy and patient/family education |

**Referral by oncology team to social work and counseling services, case management, or patient navigation**

**Follow-up and communication with primary oncology team, primary care physician, and family/caregivers**

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

---

**Social work and counseling services include mental health care as described in the psychological/psychiatric treatment guidelines (See DIS-5).**
Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Social work and counseling services include mental health care as described in the psychological/psychiatric treatment guidelines (See DIS-5).

DIS-24
CHAPLAINCY CARE

CHAPLAINCY ASSESSMENT

- Interpersonal conflict regarding spiritual/religious beliefs and practices
- Concerns with lack of meaning/purpose
- Struggles with morality/values
- Doubts about beliefs
- Perception of being attacked by evil
- Dealing with issues of forgiveness
- Concerns about relationship with the sacred
- Concerns about dying/death and/or afterlife
- Grief/loss
- Feelings of worthlessness or being a burden
- Loneliness
- Conflict between religious beliefs and recommended treatment
  - Ritual needs

INTERVENTIONS BASED ON ASSESSMENT

- Spiritual/existential support/care
- Spiritual/existential counseling
- Spiritual/existential education (including resources)
- Spiritual/existential ritual
- Meditation and/or prayer
- Referral to spiritual/existential community resources (eg, specific faith community, spiritual director, pastoral psychotherapist)
- Referral to other health care professional (eg, palliative care, mental health professional)

Follow-up and communication with primary oncology team, primary care physician, and family/caregivers

Referral by oncology team to chaplaincy care

---


Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
The Commission on Cancer’s accreditation standards include screening all patients with cancer for psychosocial distress and referral for psychosocial care as needed.9

- Recommend creation of a work group/cancer committee, which should be composed of multiple disciplines’ representatives, including but not limited to physician champions, nurses, psychologists, information technology experts, administrative leadership, social workers, and chaplaincy.
- Explicit support and backing of the institutional leadership is essential. The committee should identify and organize advocates and institutional stakeholders who will support the implementation of the program. A small-scale pilot program may be a preferable way to test the screening process before a larger scale implementation is put in place.

The following should be considered:
- Already existing resources (eg, screening tools or programs already in place)
- Current workflows, processes, and available technologies

Various distress screening tools have been developed, including the NCCN Distress Thermometer and Problem List (DIS-A). The cancer committee should select the most appropriate screening tool to be administered in its setting.
- Standardized, validated instruments, or tools with established clinical cutoffs, are recommended.
- Determine the cutoff score or specific problems that will be used to identify distressed patients.
- Determine the frequency of screening.
- Develop a response algorithm (ie, who is alerted to screening results, how information is processed, triggering of appropriate referrals).
- Develop a process in which distress screening results are made known to critical members of the care team, including such strategies as incorporating the results into the patient’s medical record.
- Develop results thresholds for generating respective referrals. These may vary based on types of services available and their capacity.
- Consider incorporating distress screening into the institutions’ quality improvement and assessment process (eg, distress screening becomes a measurable quality metric).
- Distress screening and response to results data should be tracked and can be used for further improvements, as well as expansion of needed services.

4Rodin G. From evidence to implementation: The global challenge for psychosocial oncology. Psychooncology 2018;27:2310-2316.
### INSTITUTIONAL EVALUATION OF STANDARDS OF CARE

<table>
<thead>
<tr>
<th>INTERVENTIONS</th>
<th>OUTCOMES</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Interdisciplinary committee tailors standards to institutional setting</td>
<td></td>
</tr>
<tr>
<td>• Distress Thermometer (0–10) and Problem List screening tool in clinics and inpatient setting</td>
<td></td>
</tr>
<tr>
<td>• Problem list</td>
<td></td>
</tr>
<tr>
<td>• Education of primary oncology teams via rounds and liaison with nurses and social workers</td>
<td></td>
</tr>
<tr>
<td>• Clarification of available resources</td>
<td></td>
</tr>
<tr>
<td>• CQI studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surveys</td>
</tr>
<tr>
<td></td>
<td>Professional Attitudes Knowledge Assessment</td>
</tr>
<tr>
<td></td>
<td>Patient Reduced distress, satisfaction (CQI survey of impact)</td>
</tr>
</tbody>
</table>

1Based on implementation/evaluation of pain management guidelines.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Discussion

Table of Contents
Overview ................................ ................................ ......................... MS-2
Literature Search Criteria and Guidelines Update Methodology ............. MS-2
Psychosocial Problems in Adult Patients with Cancer ....................... MS-2
Barriers to Distress Management in Cancer ................................ MS-3
NCCN Guidelines® for Distress Management ................................ MS-4
The New Standard of Care for Distress Management in Cancer .......... MS-4
Recommendations for Implementation of Standards and Guidelines MS-5
Screening Tools for Distress and Meeting Psychosocial Needs .......... MS-7
The Distress Thermometer ................................ ............................... MS-8
The Problem List ................................ ................................ .......... MS-8
Cognitive Impairment ................................ ................................. MS-9
Fertility ................................ ................................ ..................... MS-10
Substance Use Disorder ................................ ............................... MS-10
Financial Worries ................................ ................................ ...... MS-10
Initial Screening by Oncology Team ................................ ............... MS-10
Psychological/Psychiatric Treatment by Mental Health Professionals .. MS-12
................................ ................................ ................................ .. MS-12
Psychosocial Interventions ................................ ............................. MS-12
Cognitive Behavioral Therapy ................................ ...................... MS-12
Supportive Psychotherapy ................................ ........................... MS-13
Psychoeducation ................................ ................................ .......... MS-13
Family and Couples Therapy ................................ ...................... MS-13
Pharmacologic Interventions ................................ ...................... MS-14
Antidepressants ................................ ................................ ........ MS-14
Benzodiazepines ................................ ................................ ...... MS-14
Antipsychotics ................................ ................................ .......... MS-14
Exercise ................................ ................................ .................... MS-15
Complementary and/or Integrative Therapies .................................. MS-15
Psychological/Psychiatric Treatment Guidelines ............................... MS-15
Neurocognitive Disorders ................................ ............................... MS-16
Depressive and Bipolar-Related Disorders ................................ MS-17
Schizophrenia Spectrum and Other Psychotic Disorders ............... MS-18
Anxiety Disorders and Obsessive Compulsive and Related Disorders .. MS-18
Trauma- and Stressor-Related Disorders ................................ MS-19
Substance-Related and Addictive Disorders ................................ MS-20
Personality Disorders ................................ ................................ MS-20
Social Work and Counseling Services .......................................... MS-21
Spiritual and Chaplaincy Care ................................ ...................... MS-21
Oncologist Burnout ................................ ................................ .... MS-22
Summary ................................ ................................ ...................... MS-23
References ................................ ................................ ................... MS-24
Overview

In the United States, it is estimated that there are more than 16.9 million individuals with a history of cancer,1 with a total of 1,806,590 new cancer cases estimated to occur in 2020.2 All patients experience some level of distress associated with the cancer diagnosis and the effects of the disease and its treatment regardless of the stage of disease. Distress can result from the reaction to the cancer diagnosis and to the various transitions throughout the trajectory of the disease, including during survivorship. Clinically significant levels of distress occur in a subset of patients, and identification and treatment of distress are of utmost importance.

These NCCN Guidelines for Distress Management discuss the identification and treatment of psychosocial problems in patients with cancer. They are intended to assist oncology teams to identify patients who require referral to psychosocial resources and to give oncology teams guidance on interventions for patients with mild distress. These guidelines also provide guidance for social workers, certified chaplains, and mental health professionals by describing treatments and interventions for various psychosocial problems as they relate to patients with cancer.

Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Guidelines for Distress Management, an electronic search of the PubMed database was performed to obtain key literature, using the following search terms: (cancer distress) or (cancer depression) or (cancer anxiety) or (cancer dementia) or (cancer delirium) or (cancer depressive) or (cancer bipolar) (cancer post-traumatic stress) or (cancer acute stress) or (cancer adjustment disorder) or (cancer obsessive-compulsive disorder) or (cancer panic disorder) or (cancer schizophrenia) or (cancer psychotic disorder) or (cancer substance abuse) or (cancer substance dependence) or (cancer substance addiction) or (cancer personality disorder) or (cancer social work) or (cancer spiritual) or (cancer chaplain). The PubMed database was chosen because it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.3

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Practice Guidelines; Randomized Controlled Trials; Meta-Analysis; Systematic Reviews; and Validation Studies.

The data from key PubMed articles and articles from additional sources deemed as relevant to these guidelines and discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts). Recommendations for which high-level evidence is lacking are based on the panel’s review of lower-level evidence and expert opinion.

The complete details of the Development and Update of the NCCN Guidelines are available at www.NCCN.org.

Psychosocial Problems in Adult Patients with Cancer

In recent decades, dramatic advances in early detection and treatment options have increased the overall survival rates in patients of all ages with cancer. At the same time, these improved treatment options are also associated with substantial long-term side effects that interfere with patients’ ability to perform daily activities, such as fatigue, pain, anxiety, and depression. In addition, the physiologic effects of cancer itself and certain anti-cancer drugs can also be non-psychological contributors to distress symptoms.4-6 Furthermore, patients with cancer may have pre-existing psychological or psychiatric conditions that affect their ability to cope with cancer. Survivors of cancer are about twice as likely to report medication use for anxiety and depression as adults who do not have a personal history of cancer.7
Overall, surveys have found that 20% to 52% of patients show a significant level of distress.\textsuperscript{8-10} The prevalence of psychological distress in individuals varies by the type and stage of cancer as well as by patient age, gender, and race.\textsuperscript{11} Further, the prevalence of distress, depression, and psychiatric disorders has been studied in many stages and sites of cancer.\textsuperscript{12-17} Cancers of the head and neck may be particularly distressing since treatment may be disfiguring and associated with impacts on essential functions such as eating, swallowing, breathing, and speaking.\textsuperscript{18} Depression is also common in pancreatic cancer, a disease often associated with a poor prognosis.\textsuperscript{19}

The panel identified characteristics associated with psychosocial distress. Patients at increased risk for moderate or severe distress are those with a history of psychiatric disorder, current depression, or substance use disorder and those with cognitive impairment, severe comorbid illnesses, uncontrolled symptoms, communication barriers, prior trauma and/or abuse (physical, sexual, emotional, and/or verbal), or social issues. Social issues/risk factors include younger age, recent immigration, living alone, loss of housing or living environment, and having young children. Learning about genetic/familial risk of cancer is also associated with distress.\textsuperscript{20,21}

Distress is a risk factor for non-adherence to cancer treatment.\textsuperscript{22,23} In addition to decreased adherence to treatment, failure to recognize and treat distress may lead to several problems: patients may have trouble making decisions about treatment and may make extra visits to the physician’s office and emergency room, which takes more time and causes greater stress to the oncology team.\textsuperscript{24,25} An analysis of 1036 patients with advanced cancer showed that distress is associated with longer hospital stays ($P = .04$).\textsuperscript{26} Distress in patients with cancer also leads to poorer quality of life and may even negatively affect survival.\textsuperscript{27-30} Furthermore, survivors with untreated distress have poorer compliance with surveillance screenings and are less likely to exercise and quit smoking.\textsuperscript{31} Early evaluation and screening for distress leads to early and timely management of psychological distress, which in turn improves medical management.\textsuperscript{32,33} A randomized study showed that routine screening for distress, with referral to psychosocial resources as needed, led to lower levels of distress at 3 months than did screening without personalized triage for referrals.\textsuperscript{34} Those with the highest level of initial distress benefitted the most. Overall, early detection and treatment of distress lead to better adherence to treatment, better communication, fewer calls and visits to the oncologist’s office, and avoidance of patients’ anger and development of severe anxiety or depression.

**Barriers to Distress Management in Cancer**

Many patients with cancer who are in need of psychosocial care are not able to get the help they need because of the under-recognition of patients’ psychological needs by the primary oncology team and lack of knowledge of community resources.\textsuperscript{35} The need is particularly acute in community oncologists’ practices where there are often fewer psychosocial resources.

An additional barrier to patients’ receiving the psychosocial care they require is the stigma associated with psychological problems. For many centuries, patients were not told their diagnosis of cancer due to the stigma attached to the disease. Since the 1970s, this situation has changed and patients are well aware of their diagnosis and treatment options.\textsuperscript{36} Many patients, however, may be reluctant to reveal emotional problems to the oncologist. The words “psychological,” “psychiatric,” and “emotional” may be as stigmatizing as the word “cancer.” The word “distress” is less stigmatizing and more acceptable to patients and oncologists, but psychological issues remain stigmatized even in the
context of coping with cancer. Consequently, patients often do not tell their physicians about their distress and physicians do not inquire about the psychological concerns of their patients. The recognition of patients’ distress has become more difficult as cancer care has shifted to the ambulatory setting, where visits are often short and rushed. These barriers prevent distress from receiving the attention it deserves, despite the fact that distress management is a critical component of the total care of the person with cancer.

NCCN Guidelines® for Distress Management

A major milestone in the improvement of psychosocial care in oncology was made by NCCN when it established a panel to develop clinical practice guidelines, using the NCCN format. The panel began to meet in 1997 as an interdisciplinary group. The clinical disciplines involved were: oncology, nursing, social work and counseling, psychiatry, psychology, and clergy. A patient advocate was also on the panel. Traditionally, clergy have not been included on NCCN Guidelines panels, but NCCN recognized that many distressed patients prefer to speak with a certified chaplain.37

The first step was to understand why this area has been so difficult to develop. The panel members decided that words like “psychiatric” or “psychological” are stigmatizing; patients and oncologists were reluctant to label any symptoms or patients as such. The way around this barrier was developed by using a term that would feel “normal” and non-stigmatizing. This led to the first published guidelines in 1999 for the management of distress in patients with cancer. This accomplishment provided a benchmark, which has been used as a framework in the handbook for oncology clinicians published by the IPOS (International Psycho-Oncology Society) Press.38

The panel defines distress as a multifactorial, unpleasant experience of a psychological (ie, cognitive, behavioral, emotional), social, spiritual, and/or physical nature that may interfere with one’s ability to cope effectively with cancer, its physical symptoms, and its treatment. Distress extends along a continuum, ranging from common, normal feelings of vulnerability, sadness, and fears to problems that can become disabling, such as depression, anxiety, panic, social isolation, and existential and spiritual crisis.

Recommendations in the guidelines are based on evidence and on consensus among panel members. In addition to the guidelines for oncologists, the panel established guidelines for social workers, certified chaplains, and mental health professionals (psychologists, psychiatrists, psychiatric social workers, and psychiatric nurses).

The New Standard of Care for Distress Management in Cancer

Psychosocial care had not been considered as an aspect of quality cancer care until the publication of a 2007 National Academy of Medicine (NAM) (formerly the Institute of Medicine) report, Cancer Care for the Whole Patient,39 which is based on the pioneering work of the NCCN Panel. Psychosocial care is part of the standard for quality cancer care and should be integrated into routine care.39-41 The NAM report supported the work of the NCCN Guidelines for Distress Management by proposing a model for the effective delivery of psychosocial health services that could be implemented in any community oncology practice:

- Screening for distress and psychosocial needs;
- Making and implementing a treatment plan to address these needs;
- Referring to services as needed for psychosocial care; and
- Reevaluating, with plan adjustment as appropriate.
In August 2012, the Commission on Cancer (CoC) of the American College of Surgeons (ACS) released new accreditation standards for hospital cancer programs. Their patient-centered focus now includes screening all patients with cancer for psychosocial distress. These standards are required for accreditation, were enacted in 2015, and were updated in 2016 (https://www.facs.org/quality-programs/cancer/coc/standards). According to the updated accreditation standards, institutions are expected to document and monitor their distress screening process.

The standards of care for managing distress proposed by the NCCN Distress Management Panel are broad in nature and should be tailored to the particular needs of each institution and group of patients. The overriding goal of these standards is to ensure that no patient with distress goes unrecognized and untreated. The panel based these standards of care on quality improvement guidelines for the treatment of pain. The standards of care developed by the NCCN Distress Management Panel are as follows:

- Distress should be recognized, monitored, documented, and treated promptly at all stages of disease and in all settings.
- Screening should identify the level and nature of the distress.
- Ideally, patients should be screened for distress at every medical visit as a hallmark of patient-centered care. At a minimum, patients should be screened to ascertain their level of distress at the initial visit, at appropriate intervals, and as clinically indicated, especially with changes in disease status (eg, remission, recurrence, or progression; treatment-related complications).
- Distress should be assessed and managed according to clinical practice guidelines.
- Interdisciplinary institutional committees should be formed to implement standards for distress management.
- Educational and training programs should be developed to ensure that health care professionals and certified chaplains have knowledge and skills in the assessment and management of distress.
- Licensed mental health professionals and certified chaplains experienced in the psychosocial aspects of cancer should be readily available as staff members or by referral.
- Medical care contracts should include adequate reimbursement for services provided by mental health professionals.
- Clinical health outcomes measurements should include assessment of the psychosocial domain (eg, quality of life; patient and family satisfaction).
- Patients, families, and treatment teams should be informed that distress management is an integral part of total medical care and includes appropriate information about psychosocial services in the treatment center and in the community.
- Finally, the quality of distress management programs/services should be included in institutional continuous quality improvement (CQI) projects.

Patients and families should be made aware that this standard exists and that they should expect it in their oncologist's practice. The website for the Alliance for Quality Psychosocial Cancer Care, a coalition of professional and advocacy organizations whose goal is to advance the recommendations from the NAM report, has hundreds of psychosocial resources for health care professionals, patients, and caregivers, searchable by state (http://www.wholecancerpatient.org/).

Recommendations for Implementation of Standards and Guidelines

A 2013–2014 survey of applicants for a distress screening cancer education program, spanning 70 institutions, showed that fewer than half
of these institutions had not yet begun implementation of a distress screening program. A 2014 survey of 55 cancer centers in the United States and Canada showed that adherence to an institution’s distress screening protocol (ie, screening with appropriate documentation) occurred 63% of the time. Another 2014 survey of 2134 members of the Association of Oncology Social Work (AOSW) who were also employees of a CoC-accredited cancer program showed that most programs now have procedures in place to address psychosocial care and are successful in identifying psychosocial needs in patients and appropriately addressing these needs. However, programs tend to be less successful with follow-up of psychosocial care and training of providers regarding psychosocial care. A 2012 survey completed by 20 NCCN Member Institutions showed that most institutions do not formally keep track of the number of patients who utilize psychosocial care and/or services, which limits the ability to ensure that centers are adequately implementing standards of psychosocial care.

The MD Anderson Cancer Center published a 2010 report on its efforts to implement the integration of psychosocial care into clinical cancer care. The authors outline strategies they used to accomplish the required cultural shift and describe the results of their efforts. Other groups have also described their efforts toward implementing psychosocial screening in various outpatient settings. Surveys and interviews with clinical staff have identified barriers to adoption of distress screening and found that time, staff uncertainties, competing demands, and ambiguous accountability are some of the biggest barriers. A survey of oncology nurses also found that nurses who were familiar with these NCCN Guidelines for Distress Management were more comfortable discussing distress.

Institutions should have a framework in place to deliver psychosocial care, in order to effectively manage distress in patients who would benefit from psychosocial services. Some initiatives have been developed to assist institutions with implementation of standards for distress screening and psychosocial care. Quality indicators can be used to determine the quality of psychosocial care given by a clinic or office. The Quality Oncology Practice Initiative (QOPI) was started in 2002 by ASCO as a pilot project and became available to all ASCO member medical oncologists in 2006. A 2008 manuscript showed that practices participating in QOPI demonstrated improved performance, with initially low-performing practices showing the greatest improvement. Blayney and colleagues from the University of Michigan Rogel Cancer Center reported that QOPI can be adapted for use in practice improvement at an academic medical center.

Additional guidance for the implementation and dissemination of the new NAM standards has been published. In Canada, routine psychosocial care is part of the standard of care for patients with cancer; emotional distress is considered the sixth vital sign that is checked routinely along with pulse, respiration, blood pressure, temperature, and pain. A national approach has been used to implement screening for distress in Canada. Its strategies have been described in the extant literature. Groups in Italy, France, the Netherlands, and Japan have also described results of their preliminary efforts toward the implementation of psychosocial distress screening.

The panel has identified some principles of implementation to guide institutions in development of a distress screening protocol and process for appropriate referral and follow-up. These principles include the following:

- Creation of an interdisciplinary work group/committee, which ideally would include physicians, nurses, psychologists, information technology experts, social workers, chaplains, and administrative leadership.
Mandatory support from institutional leadership

Development and execution of a pilot program prior to any large-scale implementation

Consideration of the institution’s already existing resources and current workflow/processes

Distress screening should be considered a measurable quality metric. Therefore, distress screening can be incorporated into institutions’ quality improvement and assessment processes. Some results have caused doubt for some regarding the efficacy of distress screening for improving patient outcomes. For instance, a systematic review failed to find evidence that screening improved distress levels over usual care in patients with cancer. Criticisms of this review include the inappropriately narrow inclusion criteria and the focus on only distress as an outcome. A second more recent systematic review, published in the Cochrane Database of Systematic Reviews, also failed to find evidence supporting the benefits of distress screening. However, the study investigators caution that the quality of evidence is low, with more uniformity needed in outcomes and reporting. A third systematic review found that trials reporting a lack of benefit of distress screening in patients with cancer lacked appropriate follow-up care of distressed patients, while trials that linked screening with mandatory referral or intervention showed improvements in patient outcomes.

Results of these three studies show that screening, while a critical component of psychosocial care, is not sufficient to impact patient outcomes without adequate follow-up referrals and treatment. Indeed, a randomized controlled trial (RCT) examining the effects of screening on 568 patients with cancer receiving radiotherapy showed that screening alone does not significantly affect distress and quality of life, but earlier referral to mental health professionals was associated with better outcomes (ie, greater health-related quality of life, less anxiety). For implementation of a distress screening protocol, an ideal frequency of screening should be identified, and institutions should develop a process for generating referrals and alerting the appropriate staff based on screening results. Whether or not screening is occurring, how often, and whether or not appropriate referrals are generated, should be tracked. This information can be used by institutions to implement improvements in the process and potentially expand needed services.

Screening Tools for Distress and Meeting Psychosocial Needs

Identification of a patient’s psychological needs is essential to develop a plan to manage those needs. In routine clinical practice, time constraints and the stigma related to psychiatric and psychological needs often inhibit discussion of these needs. It is critical to have a fast and simple screening method that can be used to identify patients who require psychosocial care and/or referral to psychosocial resources. The NCCN Distress Management Panel developed such a rapid screening tool, as discussed below.

Screening tools have been found to be effective and feasible in reliably identifying distress and the psychosocial needs of patients. Completion of a psychosocial screening instrument may lead to earlier referral to social work services. Mitchell and colleagues reported that ultra-short screening methods (Patient Health Questionnaire-2 [PHQ-2] or the NCCN Distress Thermometer [DT]) were acceptable to about three quarters of clinicians. Other screening tools have also been described. Automated touch screen technologies, interactive voice response, and web-based assessments have also been used for psychosocial and symptom screening of patients with cancer.
The Distress Thermometer

The NCCN Distress Management Panel developed the DT, a now well-known tool for initial screening of 0 (no distress) to 10 (extreme distress), which is similar to the successful rating scale used to measure pain. The DT serves as an initial, single-item question screen, which identifies distress coming from any source, even if unrelated to cancer. The DT can be administered in a variety of settings, such as through a patient portal or given by a receptionist or medical assistant.

Patients are asked to indicate the number that best describes how much distress they have experienced over the past week, on a scale of 0 to 10. If the patient’s distress level is mild (score is <4 on the DT), the primary oncology team may choose to manage the concerns with usual clinical supportive care. If the patient’s distress level is 4 or higher, a member of the oncology team will look at the Problem List (see below) to identify key issues of concern and ask further questions to determine the best resources (psychiatry, psychology, social work, or chaplaincy professionals) to address the patient’s concerns.

The DT has been validated by many studies in patients with different types of cancer, in different settings, and in different languages, cultures, and countries. The DT has shown good sensitivity and specificity. A meta-analysis of 42 studies with greater than 14,000 patients with cancer found the pooled sensitivity of the DT to be 81% (95% CI, 0.79–0.82) and the pooled specificity to be 72% (95% CI, 0.71–0.72) at a cut-off score of 4. However, an analysis including 181 Dutch women who completed the DT within one month following breast cancer diagnosis showed that sensitivity was 95% and specificity was only 45% when the recommended cut-off score of 4 was used. Study investigators suggested that a cut-off score of 7 was optimal, with sensitivity being 73% and specificity being 84%. Using a higher cut-off score would reduce the number of false positives.

While the DT is not a screening tool for psychiatric disorders, it has demonstrated concordance with the Hospital Anxiety and Depression Scale (HADS) and the Depression Anxiety and Stress Scale-21. A study including 463 patients with cancer showed that the DT does not accurately detect mood disorders (based on DSM-IV criteria; AUC = 0.59) compared to the PHQ-2 (AUC = 0.83 with a cut-off score of ≥3) and PHQ-9 (AUC = 0.85 with a cut-off score of >9), which are both validated for screening patients with depressive symptoms.

The NCCN DT and Problem List are freely available for non-commercial use. In addition, the NCCN patient website includes a patient-friendly description of distress with a copy of the tool (http://www.nccn.org/patients/resources/life_with_cancer/distress.aspx).

NCCN also has verified translations of the DT and Problem List in various languages that are freely available online (https://www.nccn.org/global/international_adaptations.aspx).

The Problem List

The screening tool developed by the NCCN Distress Management Panel includes a 39-item Problem List, which is on the same page as the DT. The Problem List asks patients to identify their problems in five different categories: practical, family, emotional, spiritual/religious, and physical. The panel notes that the Problem List may be modified to fit the needs of the local population.

An analysis of the DT and Problem List including principal component analysis, logistic regression, and classification and regression tree analyses showed that endorsement of Problem List items associated with emotion (ie, sadness, worry, depression, fears, nervousness, sleep), physical function (ie, transportation, bathing/dressing, breathing, fatigue, getting around, memory/concentration, pain), and support (ie, spiritual/religious concerns, insurance/finances, dealing with partner) were
significantly associated with moderate or severe distress ($P < .001$, $P = .003$, and $P = .013$, respectively).\textsuperscript{108} Two studies validated a version of the DT with an expanded problems list.\textsuperscript{109,110} Tuinman and colleagues validated the DT with the 46-item Problem List in a cross-sectional group of 227 patients with cancer.\textsuperscript{110} Graves and colleagues validated the DT with an adapted problems list with two new problem categories (information concerns and cognitive problems) in patients with lung cancer.\textsuperscript{109}

**Cognitive Impairment**

"Memory/concentration problems" is one item on the Problem List. Cognitive impairment is common in patients with primary central nervous system (CNS) cancers, due to the effects of brain tumors themselves and the effects of treatment targeted to the brain.\textsuperscript{111,112} Evidence has shown that chemotherapy-related cognitive dysfunction is also prevalent in patients with non-CNS cancers and without brain metastases.\textsuperscript{113-117} Chemotherapy can cause subtle cognitive changes, which have been studied primarily in patients with breast cancer or lymphoma. These changes can continue over years and at times, when more severe, can impact quality of life and function. One study, however, showed that patients with breast cancer who received systemic adjuvant therapy did not report significantly greater cognitive impairment 7 to 9 years after treatment, compared to patients with breast cancer who did not receive systemic adjuvant therapy ($N = 1889$), when statistically controlling for menopausal status and sociodemographic and clinical covariates.\textsuperscript{118} The underlying mechanisms for chemotherapy-induced cognitive changes are not known. Studies have reported elevated levels of cytokines or DNA damage as some of the possible mechanisms.\textsuperscript{119} Furthermore, changes in brain activity have been observed in patients following chemotherapy, suggesting that direct damage to the brain may contribute to chemotherapy-induced cognitive decline.\textsuperscript{120}

Evidence suggests that cancer itself and therapies other than chemotherapy, such as hormone therapy, can cause cognitive impairments in patients with cancer.\textsuperscript{121-124} A meta-analysis including 14 studies with 417 prostate cancer patients showed that androgen deprivation therapy negatively impacts performance of visuomotor tasks.\textsuperscript{125} A national cross-sectional study found that a history of cancer is independently associated with a 40% increase in the likelihood of self-reported memory problems.\textsuperscript{126} A case-control study ($N = 226$) showed that patients with breast cancer may experience some cognitive impairment prior to beginning treatment, and this impairment may be due to post-traumatic stress symptoms.\textsuperscript{127,128} A better understanding of the mechanisms that cause cancer-related cognitive impairment is essential for the development of treatments to improve cognitive function and quality of life in patients with cancer.\textsuperscript{111,112,129}

There is no standard treatment for the management of cognitive changes in patients with cancer, and intervention studies to date have been limited by methodologic flaws such as a small sample size, poor generalizability, and lack of a proper control group.\textsuperscript{115,130} Cognitive behavioral therapy (CBT), cognitive rehabilitation programs, compensatory strategy training, and exercise may be effective interventions to improve cognitive function in patients with cancer.\textsuperscript{115,130-134} In addition, some studies have shown that the use of psychostimulants such as methylphenidate and modafinil improved cognitive function in patients with cancer.\textsuperscript{135-140} Donepezil, a reversible acetylcholinesterase inhibitor (approved to treat mild to moderate dementia in patients with Alzheimer’s disease) also improved cognitive function, mood, and health-related quality of life in patients with primary low-grade glioma.\textsuperscript{141} Further placebo-controlled trials are needed to confirm these preliminary findings.\textsuperscript{115,136}

In October 2006 the International Cognition and Cancer Task Force (ICCTF), comprised of a multidisciplinary group of health professionals
Distress Management

and health advocates, was formed. The mission of ICCTF is to advance understanding of the impact of treatment-related cognitive and behavioral functioning in patients with non-CNS cancers. ICCTF also has a website (www.icctf.com) to provide up-to-date information to both physicians and patients seeking assistance in the management of cognitive symptoms associated with cancer treatment.

The NCCN Guidelines for Survivorship (available at www.NCCN.org) contain more information on this topic, with recommendations for the management of cognitive dysfunction in survivors.

Financial Worries

Financial worries in cancer survivors may be more common in patients who are younger, uninsured, have a lower income, and were treated recently. It is important for the primary oncology team to be aware of potential financial worries facing patients undergoing distress screening.

Initial Screening by Oncology Team

The panel recommends that all patients be screened prior to clinical visits using a simple tool. While there are several types of screening tools, the DT and the accompanying Problem List are recommended to assess the level of distress and to identify causes of distress. If the patient's distress is moderate or severe (thermometer score ≥ 4), the oncology team must recognize that score as a trigger to a second level of questions, including clinical interviews and/or validated scales/screeners for anxiety and depression. A positive screen should prompt referral to a mental health professional, social worker, or spiritual counselor, depending on the problems identified in the Problem List. Common symptoms that require further evaluation are: excessive worries and fears, excessive sadness, unclear thinking, despair and hopelessness, severe family problems, social problems, and spiritual or religious concerns. Any unrelieved physical symptoms should be treated based on NCCN's disease-specific guidelines, and referral for palliative care management may also be
considered (see the NCCN Guidelines for Palliative Care, available at www.NCCN.org).

Mild distress (DT score <4) is routinely managed by the primary oncology team and represents what the panel terms "expected distress" symptoms. The symptoms that the team manages are fear and worry about the future; concerns about the illness; sadness about loss of good health; anger and the feeling that life is out of control; poor sleep, poor appetite, and poor concentration; preoccupation with thoughts of illness, death, treatment, and side effects; concerns about social roles (eg, mother, father); and spiritual or existential concerns. Many patients experience these symptoms at the time of diagnosis and during arduous treatment cycles. They might persist long after the completion of treatment. For instance, minor physical symptoms are often misinterpreted by survivors as a sign of recurrence, which causes fear and anxiety until they are reassured.

The primary oncology team is the first to deal with these distressing problems. The oncologist, nurse, and social worker each have a critical role. First and foremost, a critical component is the quality of the physician’s communication with the patient, which should occur in the context of a mutually respectful relationship so that the patient can learn the diagnosis and understand the treatment options and side effects. Adequate time should be provided for the patient to ask questions and for the physician to put the patient at ease. When communication is done well at diagnosis, the stage is set for future positive trusting encounters. It is important to ensure that the patient understands what has been said. Information may be reinforced with drawings or by recording the session and giving the recording to the patient. Communication skills training programs, for example, that teach oncology professionals how to discuss prognosis and unanticipated adverse events and how to reach a shared treatment decision, may be very helpful. In fact, in an RCT, it was found that patients of oncologists who had communication skills training were less depressed at follow-up than patients of oncologists from the control group ($P = .027$). For a comprehensive review of communication skills training, see Kissane et al.

It is important for the oncology team to acknowledge and validate that cancer presents a unique challenge and that distress is normal and expected. Being able to express distress to the staff helps provide relief to the patient and builds trust. The team needs to ensure that social supports are in place for the patient and that the patient knows about community resources such as support groups, teleconferences, and help lines. The NAM report contains a list of national organizations and their toll-free numbers. Some selected organizations that provide free information services to patients with cancer are:

- American Cancer Society: www.cancer.org
- American Institute for Cancer Research: www.aicr.org
- American Psychosocial Oncology Society: http://apos-society.org/
- Cancer Support Community: http://www.cancersupportcommunity.org (Cancer Support Community provides the Cancer Support Helpline at 888.793.9355)
- CancerCare: www.cancercare.org
- National Cancer Institute: www.cancer.gov
- Cancer.net, sponsored by ASCO: www.cancer.net

Follow-up at regular intervals or at transition points in illness is an essential part of the NCCN Guidelines for Distress Management and the NAM model for care of the whole patient.
Psychological/Psychiatric Treatment by Mental Health Professionals

Psychosocial Interventions

Psychosocial interventions have been effective in reducing distress and improving overall quality of life among patients with cancer.39,40 The 2007 NAM report noted that a strong evidence base supports the value of psychosocial interventions in cancer care.39 The review examined the range of interventions (psychological, social, and pharmacologic) and their impact on any aspect of quality of life, symptoms, or survival. The extensive review found randomized clinical trials, systematic reviews, and meta-analyses supporting the conclusion that psychosocial aspects must be integrated into routine cancer care in order to give quality cancer care. Other meta-analyses have come to similar conclusions, although more research is clearly needed.152-155 To date, psychosocial interventions for patients with cancer have disproportionately targeted women with breast cancer.152,153 More interventions targeting patients with other cancer types, or inclusion of mixed types, should be developed and evaluated. A meta-analysis including 53 studies of psychosocial interventions for patients with cancer (N = 12,323) showed that patients were more willing to participate in interventions delivered over the telephone versus in-person (P = .031) and when intervention is offered shortly after diagnosis versus later (P = .018).156 CBT, supportive psychotherapy, and family and couples therapy are three key types of psychotherapies discussed in the NAM report.39

Cognitive Behavioral Therapy

CBT involves practicing relaxation techniques, enhancing problem-solving skills, and identifying and correcting inaccurate thoughts associated with feelings. In randomized clinical trials, CBT and cognitive-behavioral stress management have been shown to effectively reduce psychological symptoms (anxiety and depression) as well as physical symptoms (pain and fatigue) in patients with cancer.157-162 A Cochrane systematic review including 28 RCTs (N = 3940) showed that CBT interventions favorably address anxiety, depression, and mood disturbance in patients with non-metastatic breast cancer.163 The quality of the evidence was low for anxiety and depression and moderate for mood disturbance, however, indicating the need for studies to use higher quality intervention methods and validated instruments for measuring outcomes. Two RCTs have demonstrated improvements in distress following web-based CBT interventions.164,165

Therapy techniques rooted in CBT may be effective in reducing depression and anxiety. Meta-analyses have examined the effects of mindfulness-based stress reduction (MBSR). Two meta-analyses show that MBSR reduces distress.166,167 One of these analyses, which included 29 RCTs and 3274 patients showed that larger effects were found for studies that adhered to an intervention manual, included younger patients, used a passive control group, and used a shorter follow-up interval.167 Two meta-analyses including RCTs with patient with breast cancer showed that MBSR may impact anxiety and depression in the short-term only.168,169 Behavioral activation, which is focused on decreasing avoidance and increasing engagement in activities, is associated with improvements in depression.170 Some small studies have shown that behavioral activation therapy may improve depression and anxiety in patients with cancer, but larger studies are needed.171,172 Finally, results from small randomized trials including women with breast cancer show that problem solving therapy, which helps individuals focus on healthy coping methods and developing action plans to address obstacles, may improve depression in these patients.172,173

Ferguson and colleagues have developed a brief CBT intervention (Memory and Attention Adaptation Training [MAAT]) aimed at helping breast cancer survivors manage cognitive dysfunction associated with adjuvant chemotherapy.174 In a randomized study, the study investigators found that patients in the intervention arm had improved verbal memory
performance and spiritual well-being. A randomized trial in which MAAT delivered through video conference was compared to supportive therapy in 47 survivors of breast cancer showed that MAAT improved self-reported perceived cognitive impairments ($P = .02$) and neuropsychological processing speed ($P = .03$), compared to supportive therapy.

**Supportive Psychotherapy**
Supportive psychotherapy, aimed at flexibly meeting patients’ changing needs, is widely used. Different types of group psychotherapy have been evaluated in clinical trials among patients with cancer. Meaning-centered group psychotherapy, designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace, and purpose in their lives (even as they approach the end of life), has also been shown to reduce psychological distress among patients with advanced cancer. Dignity therapy, which has been designed for patients with a terminal diagnosis, has been evaluated in a small number of RCTs and quasi-experimental studies. Effects on psychological well-being and quality of life are inconsistent, with additional research being needed in this area. An RCT for patients with renal cell carcinoma ($N = 277$) showed that expressive writing reduces self-reported cancer-related symptoms (eg, pain, nausea, fatigue) and improves physical functioning. Secondary analyses from this study showed that the patients who benefited the most from the expressive writing intervention had both greater depressive symptoms and greater social support, as measured at baseline.

Interventions incorporating internet support groups have become popular, with a Cochrane review including 6 studies with 492 women with breast cancer showing a small to moderate effect on depression, based on low-quality evidence. None of the 6 studies included in the review assessed emotional distress specifically, and results from 2 studies showed no significant effect on anxiety when comparing the intervention and control groups. Results of an RCT that included an internet support group with a prosocial component showed that this intervention did not reduce depression and anxiety in women with nonmetastatic breast cancer ($N = 184$). One systematic review showed that internet peer support interventions that are unmoderated may even be detrimental.

**Psychoeducation**
Psychoeducational interventions are those that offer education to those with specific psychological disorders or physical conditions. Psychoeducational interventions for patients with cancer may be general, such as providing information regarding stress management and healthy living (eg, nutrition, exercise), while other interventions may be more specific to the cancer type. A meta-analysis examining 19 psychoeducational interventions with 3857 cancer patients showed small post-treatment effects overall for emotional distress, anxiety, depression, and quality of life. The only significant effects at long-term follow-up were for quality of life. Another meta-analysis including 11 studies of psychoeducational interventions for patients with gynecologic cancers showed effectiveness for depressive symptoms. Motivational interviewing is a patient-centered approach in which a mental health professional offers empathy as the patient explores ambivalence regarding behavior change. One meta-analysis showed that motivational interviewing may be effective for patients with cancer for behaviors such as fruit/vegetable consumption, physical activity, smoking cessation, stress management, and sleep. Psychoeducation interventions that offer education regarding symptom management may also be effective when delivered via the internet.

**Family and Couples Therapy**
A cancer diagnosis causes distress in partners and family members as well as the patient. Psychosocial interventions aimed at patients and their families together might lessen distress more effectively than individual interventions. In a longitudinal study of couples coping with early-stage
breast cancer, mutual constructive communication was associated with less distress and more relationship satisfaction for both the patients and partners compared to demand/withdraw communication or mutual avoidance, suggesting that training in constructive communication would be an effective intervention.195

Some systematic reviews have been carried out to assess the efficacy of therapy involving patients’ close others. A meta-analysis including 23 RCTs showed that patient-caregiver interventions were associated with improvements in patient quality of life, marital functioning, depression, and anxiety.196 A meta-analysis focusing specifically on couple-based interventions for patients with cancer and their spouses (N = 12) showed that these interventions improved depression, anxiety, and marital satisfaction, compared to control groups.197 A systematic review of 23 studies that assessed the efficacy of psychosocial interventions for couples affected by cancer found evidence that couples therapy might be at least as effective as individual therapy.198 Another systematic review examining the effects of 10 interventions for couples coping with breast cancer showed that, though results are mixed, these interventions tend to yield at least some benefit.199

Pharmacologic Interventions
Psychotropic medications help to manage depression and anxiety in the cancer setting. They have great benefits, as well as risks.

**Antidepressants**
Antidepressants help to manage both depression and anxiety in adult patients with cancer and are commonly used in these settings.200-206 In RCTs, selective serotonin reuptake inhibitors (SSRIs) have efficacy in improving depressive symptoms in patients with cancer.207,208 Of note, antidepressants usually must be taken daily, not intermittently, and require 4 to 6 weeks to take full effect. A discontinuation syndrome of malaise, dizziness, or lightening-like pains can occur when these medications are stopped suddenly. While not dangerous, this syndrome can be minimized by decreasing the antidepressant dose slowly over the course of weeks to months, under the supervision of a clinician. Antidepressants can sometimes interact with commonly used oncologic and other types of medications. For instance, some antidepressants prolong the cardiac QT interval and can interact with anti-cancer agents that also do so.

**Benzodiazepines**
Acute anxiety can interfere with cancer treatment (eg, anticipatory nausea and vomiting with chemotherapy; claustrophobia with radiographic assessment; anxiety exacerbating pain or sleep disturbances; anxiety impeding medical decision-making or treatment adherence; and existential anxiety). Benzodiazepines, which are fast-acting, are prescribed commonly in the cancer setting for patients with acute anxiety.209,210 Despite their efficacy, benzodiazepines have notable risks including confusion, ataxia leading to falls and motor vehicle crashes, and addiction. Such sequelae are magnified in older adults and in patients who are frail. For these reasons, benzodiazepine use should not be undertaken lightly, and dose reduction should be considered to minimize memory difficulties, sedation, and tolerance. When used chronically, benzodiazepines should be withdrawn gradually over the course of weeks to months in order to avoid a withdrawal syndrome of insomnia, tremulousness, agitation, delirium, or seizures.

**Antipsychotics**
Antipsychotics are sometimes used in the cancer setting to manage fear, agitation, psychosis, sleep, steroid-related lability, and delirium. Risks of antipsychotics include movement disorders, restlessness, sedation, orthostatic hypotension, and asthenia. In dementia-related psychosis, which may occur in older adult patients, antipsychotics increase risk of death, which is noted in a black box warning. Some antipsychotics prolong
the cardiac QT interval\textsuperscript{211} and may promote metabolic disturbance by impacting lipid metabolism.\textsuperscript{212}

**Exercise**

Exercise during and after cancer treatment can improve cardiovascular fitness and strength and can have positive effects on balance, body composition, and quality of life.\textsuperscript{213-215} A systematic review of 20 meta-analyses showed that there was a statistically significant effect of exercise on depression in cancer survivors in 63\% of the meta-analyses.\textsuperscript{216} However, most of the effect sizes were small, with low to moderate quality of evidence. Two meta-analyses\textsuperscript{217,218} reported a greater pooled effect estimate for studies in which exercise took place after primary treatment was completed, compared to studies in which exercise was done during treatment. A Cochrane systematic review of patients with hematologic malignancies only showed that aerobic exercise may reduce depression but not anxiety.\textsuperscript{219,220} Another meta-analysis examining the effects of exercise during or after chemotherapy treatment (10 studies with 838 participants) also showed an impact on depression (\( P = .04 \)) but not anxiety (\( P > .05 \)).\textsuperscript{221} The quality of the evidence in this area is low, as larger RCTs and longer follow-up periods are needed. Cancer-related fatigue, which may be exacerbated by distress, is also positively impacted by exercise (see the NCCN Guidelines for Cancer-Related Fatigue, available at [www.NCCN.org]\textsuperscript{222,223}.

**Complementary and/or Integrative Therapies**

Regarding complementary and/or integrative therapies for patients with cancer, a systematic review showed that meditation, yoga, relaxation with imagery, massage, and music therapy may be helpful for patients with depressive disorders who have breast cancer.\textsuperscript{224,225} Music therapy, meditation, and yoga may also be used to reduce anxiety in patients with breast cancer.\textsuperscript{224,225} A systematic review including 52 randomized and quasi-randomized trials with 3731 patients showed that music therapy benefits patients with anxiety (\( P < .001 \)).\textsuperscript{226} Findings from this review also indicated that music therapy may positively affect patients with depression, but the quality of the evidence was low.

A meta-analysis including 16 RCTs with 930 patients with breast cancer showed that yoga may reduce depression (standardized mean difference [SMD], -0.17; 95\% CI, -0.32 to -0.01; \( P < .001 \)) and anxiety (SMD, -0.98; 95\% CI, -1.38 to -0.57; \( P < .001 \)) in these patients.\textsuperscript{227} However, the methodologic quality of the studies included in this review was generally low. A Cochrane review showed that, when compared to psychosocial or educational interventions, yoga may have at least short-term effects on depression (pooled SMD, -2.29; 95\% CI, -3.97 to -0.61) and anxiety (pooled SMD, -2.21; 95\% CI, -3.90 to -0.52).\textsuperscript{228} A systematic review showed that yoga during treatment may improve distress, but this conclusion is based on only 2 RCTs.\textsuperscript{229} Large randomized studies are needed to investigate the potential impact of yoga on distress.

Based on the evidence described above, the panel recommends relaxation, meditation, and creative therapies such as art and music for patients experiencing distress.

**Psychological/Psychiatric Treatment Guidelines**

Patients scoring 4 or higher on the DT during any visit to the oncologist are referred to the appropriate supportive service (mental health, social work and counseling, or chaplaincy professionals) based on the identified problem.

Mental health professionals are expected to conduct a psychological or psychiatric evaluation that includes an assessment of the nature of the distress, changes in behavior, interpersonal problems, psychological/psychiatric history and symptoms, use of medications, substance use disorder, pain, fatigue, sleep disturbances, other physical symptoms, cognitive impairment, body image, sexual health, and capacity
for decision-making and physical safety. Demoralization, which is characterized by helplessness and loss of meaning and purpose, should be evaluated and distinguished from the presence of a depressive disorder. A psychiatrist, psychologist, nurse, advanced practice clinician, or social worker may perform the evaluation. All of these professionals are skilled in mental health assessment and treatment.

Patients with mental illness experience cancer disparities, such as increased cancer mortality rates, more advanced cancer at time of diagnosis, and more comorbidities. The panel has developed evaluation and treatment guidelines for the most commonly encountered psychiatric disorders, consistent with the classification in the most recent edition of the DSM. These disorders include neurocognitive disorders (dementia and delirium), depressive disorders, bipolar and related disorders, trauma- and stressor-related disorders (including adjustment disorders), anxiety disorders, substance-related and addictive disorders, schizophrenia spectrum and other psychotic disorders, obsessive compulsive and related disorders, and personality disorders. Psychotropic drugs are recommended throughout the guidelines to treat psychiatric disorders. It is important to note that these drugs can sometimes interact with anticancer therapies and cause adverse effects. Howard et al reviewed some of these interactions and discusses other challenges in treating cancer in patients with severe mental illness.

Patients considered to be a danger to themselves or others should receive a psychiatric consultation. Increased monitoring, safety planning, and removal of guns and other dangerous objects are warranted. Hospitalization and suicide and homicide risk evaluation may sometimes be necessary. Mental health treatment/follow-up of these patients, family education regarding safety, and assuring the safety of others is warranted. Referral to social work and counseling services or chaplaincy care may also be considered.

Additional information regarding treatment of distress and psychiatric disorders in cancer can be found in the comprehensive handbook, *Psycho-Oncology: A Quick Reference on the Psychosocial Dimensions of Cancer Symptom Management,* and the comprehensive textbook, *Psycho-Oncology.* Additional resources targeting specific age groups include the comprehensive handbooks, *Geriatric Psycho-Oncology: A Quick Reference on the Psychosocial Dimensions of Cancer Symptom Management,* and *Pediatric Psycho-Oncology: A Quick Reference on the Psychosocial Dimensions of Cancer Symptom Management,* which target management of psychological, cognitive, and social difficulties in older adults and children/adolescents, respectively. The NCCN Guidelines for Supportive Care may also be referred to as needed (available at [www.NCCN.org](http://www.NCCN.org)).

### Neurocognitive Disorders

Neurocognitive disorders that may affect patients being treated with cancer include dementia and delirium. Dementia and delirium are cognitive impairments that can severely alter the patient’s decision-making capacity. Dementia is a permanent cognitive impairment. It is not a common complication of cancer treatment, but is often present in elderly patients as a comorbid condition. A systematic review including 9 studies showed that patients with dementia are diagnosed at a later stage of cancer, receive less treatment, experience more complications, and have poorer survival, compared to patients without dementia. Dementia can be treated with cognitive rehabilitation, with or without medications, though treatment is largely behavior management.

Delirium is a short-term cognitive impairment and has been reported to occur in as many as 43% of patients with advanced cancer. Delirium is usually reversible and occurs in cancer treatment that is associated with toxicity; it is often related to medication, particularly opioids. Benzodiazepines should be used with caution, as their use may contribute
Distress Management

A prospective case-control cohort study (N = 245) showed a significant association between benzodiazepine use and development of postoperative delirium (odds ratio [OR], 3.0; 95% CI, 1.3–6.8), with stronger associations for long-acting agents (OR, 5.4; 95% CI, 1.0–29.2) and high-dose exposure (OR, 3.3; 95% CI, 1.0–11.0). A prospective observational study of 243 patients with advanced cancer who presented to an emergency department at an NCCN Member Institution showed that delirium was present in 9% of all patients, but physicians correctly diagnosed delirium in only 59% of patients experiencing delirium. Additional analyses from this study showed that patients with delirium had worse overall survival and were more likely to be hospitalized, compared to patients without delirium. A retrospective chart review of 771 palliative care consultations showed that symptoms of delirium were misinterpreted by the primary oncology team 61% of the time. Delirium is managed by attention to safety, modification of opioids or other medications, antipsychotics, behavior management, and family support and education.

The United Kingdom’s National Institute for Health and Care Excellence (NICE) issued detailed guidelines for the diagnosis, prevention, and management of delirium. In addition, a comprehensive review in The Journal of Clinical Oncology Special Series on Psychosocial Care in Cancer by Breitbart and Alici describes the evidence base for recommended pharmacologic and non-pharmacologic treatments for delirium in patients with cancer.

Depressive and Bipolar-Related Disorders

Depressive and bipolar-related disorders are common in patients with cancer and can be debilitating. A cross-sectional analysis of 2141 patients with cancer showed a 4-week prevalence rate of 6.5% (95% CI, 5.5–7.5) for a depressive or bipolar-related disorder. Depressive symptoms during cancer diagnosis and treatment may persist for as long as 2 years following diagnosis. Depressive and bipolar-related disorders are associated with poorer cancer survival.

Patients with uncontrolled depressive and bipolar-related disorders can develop suicidal tendencies. A study of over 5,000 patients at one center found that 6% of patients with cancer experienced suicidal ideation. The incidence of suicide among patients with cancer in the United States is twice that of the general population. Older patients, patients who undergo high-morbidity surgeries, and men with head and neck cancer or myeloma seem to have a higher risk of suicide. Suicide risk in patients with cancer may be highest in approximately the first two years following diagnosis. Among patients with breast cancer, suicide mortality is associated with younger age, being male, non-White non-Black race, being unmarried, having undergone surgery, having progesterone-receptor-positive disease, and shorter time elapsed since diagnosis. Among patients with colorectal cancer, suicide rates were higher among men than women. Violence may also be associated with depressive disorders, particularly when there is comorbid substance use.

Depressive and bipolar-related disorders are usually managed with psychotherapy or psychotropic medication (category 1). The evidence for these treatments has been described. In particular, a review by Li et al. in The Journal of Clinical Oncology Special Series on Psychosocial Care in Cancer comprehensively describes the evidence for recommended pharmacologic and psychosocial interventions for treating depression in patients with cancer. There is evidence that telehealth interventions can improve depression outcomes, and these may be considered in patients for whom in-person psychotherapy is not feasible or accessible. Referral to social work and counseling services, as well as  

MS-17
chaplaincy services, may also be considered. If these patients have no or only a partial response to treatment, then the chosen psychotherapeutic intervention should be re-evaluated. The following options should also be considered: 1) augmenting or changing medication; 2) electroconvulsive therapy (ECT); 3) higher level care with an intensive outpatient program; and 4) obtaining a second opinion. In ECT, electrical currents are passed through the brain in a controlled fashion, inducing a brief seizure. ECT appears to be an effective treatment of psychotic depression, mania, catatonia, and other psychiatric disorders. Although the use of ECT in cancer has not been well-studied, several case studies suggest that it can be safe and effective.

ASCO has released a clinical oncology guideline adaptation of a pan-Canadian practice guideline for the screening, assessment, and treatment of anxiety and depression in patients with cancer. The panel recommends that PHQ-2 or PHQ-9 be used to screen for depressive disorders, since these brief tools are superior to the DT for this purpose (see Screening Tools for Distress and Meeting Psychosocial Needs: Distress Thermometer, above).

**Schizophrenia Spectrum and Other Psychotic Disorders**

Psychotic disorders include hallucinations, delusions, and/or thought disorders; patients with recurrent psychotic episodes are considered to have a schizophrenia spectrum disorder. Schizophrenia spectrum and other psychotic disorders can exist as comorbidities in patients with cancer and can also be caused or exacerbated by cancer and its associated stress and treatment. In particular, corticosteroids or corticosteroid withdrawal can induce psychosis, which may be relieved by modifying dose or changing corticosteroid choice. When a patient in a long-term psychiatric facility develops cancer, there is a need for coordination of care between the psychiatric facility and the inpatient cancer facility. Special attention should be paid to the transition of a psychiatric patient who needs inpatient oncology care. The issues around continuation of psychotropic medications, when they must be stopped for surgery or chemotherapy and when they should be restarted, are important issues in total care. Evaluation for any active signs of psychosis should be considered when someone with a history of schizophrenia or a psychotic disorder is diagnosed with cancer.

When a psychotic episode occurs in a patient with cancer, differential diagnoses must be ruled out. Delirium is often confused with psychotic disorder and is much more common; dementia, depressive and bipolar-related disorders, and substance-related and addictive disorders should also be considered. When psychotic disorder or schizophrenia spectrum disorder is diagnosed, several interventions can be considered: 1) anti-psychotic medication; 2) medication for mood; 3) transfer to a psychiatric unit/hospital; or 4) ECT for psychotic depression/mania or catatonia. Antipsychotics may need to be urgently administered if there is risk to self, others, or the environment.

**Anxiety Disorders and Obsessive Compulsive and Related Disorders**

Anxiety occurs at times in most patients with cancer. A cross-sectional analysis of 2141 patients with cancer showed a 4-week prevalence rate of 11.5% (95% CI, 10.2–12.9) for any anxiety disorder. The diagnosis of cancer and the effects of the disease and its treatment are obvious sources of unease; however, anxiety may also be related to physiologic aspects of the medical condition (eg, hormone-secreting tumors; effects of certain types of medications [bronchodilators]; withdrawal from alcohol or narcotics; pain or some other distressing physical symptom). Anxiety may not be severe or problematic, but needs to be addressed when it becomes disruptive. After ruling out medical causes, the clinician should assess symptoms to determine the particular nature of the anxiety disorder(s). Generalized anxiety disorder is usually
pre-existing and may be exacerbated by illness. Panic disorder may recur during illness in a person with previous panic symptoms. Patients with cancer may also be at increased risk of agoraphobia. Obsessive-compulsive disorder is a pre-existing disorder that results in difficulty in making decisions, ruminative thoughts about illness, and fearfulness to take medication. Some patients develop phobias of needles, hospitals, and blood or conditioned nausea/vomiting related to chemotherapy. Patients with social anxiety disorder may have difficulties in communicating with medical staff. Chemotherapy-induced nausea and vomiting should be managed according to the NCCN Guidelines for Antiemesis (available at www.NCCN.org). Patients with anxiety associated with religious or spiritual concerns should be referred to chaplaincy care.

The NCCN Distress Management Panel recommends psychotherapy as a category 1 recommendation for the treatment of anxiety disorders, including obsessive compulsive disorder, after eliminating medical causes. Treatment with an antidepressant or an anxiolytic is also recommended. If there is a response to initial treatment, follow-up should occur with the primary oncology team, primary care physician, and family/caregivers. If no response or a partial response is noted, the patient should be re-evaluated and treated with different medications (an antipsychotic should be considered) with continued psychotherapy, support, and education. If there is still not a complete response, then the patient should be evaluated for depression and other psychiatric comorbidity.

The evidence for the effectiveness of these treatments has been reviewed. In a review in The Journal of Clinical Oncology Special Series on Psychosocial Care in Cancer, Traeger et al give a comprehensive description of the evidence for recommended pharmacologic and non-pharmacologic treatments for anxiety in patients with cancer.

Trauma- and Stressor-Related Disorders

Trauma and stressor-related disorders that may affect patients with cancer include post-traumatic stress disorder (PTSD), acute stress disorder, and adjustment disorder. PTSD may develop after arduous cancer treatments, during a cancer treatment that triggers a traumatic memory of a past frightening event, or just from the stress of a cancer diagnosis. As many as 12% of patients with stage I–III breast cancer have been found to have persistent PTSD. Survivors of cancer may continue to experience PTSD symptoms. A meta-analysis including 25 studies with 4189 cancer survivors (mostly survivors of breast cancer) showed that self-reported PTSD symptoms occur in 7.3% of survivors, while rates based on structured clinical interviews are 12.6% for lifetime PTSD and 6.4% for current PTSD. A PTSD diagnosis prior to cancer diagnosis or previous trauma is a risk factor for cancer-related PTSD. Acute stress disorder is diagnosed in the first month following a traumatic event, and the criteria contain a greater emphasis on dissociative symptoms. Twenty-three percent to 28% of patients diagnosed with cancer meet criteria for acute stress disorder. Adjustment disorder refers to a cluster of symptoms such as stress, depressive symptoms, and physical symptoms following a stressful life event such as cancer diagnosis and treatment. It may be diagnosed when a patient who experienced a stressful life event does not meet criteria for PTSD or acute stress disorder. Adjustment disorder occurs in 15.4% of patients in palliative care settings and in 11% to 19% of patients in oncologic and hematologic settings.

Treatment of trauma- and stressor-related disorders in patients with cancer includes psychotherapy (category 1) with or without an antidepressant and/or an anxiolytic. If this treatment yields no response or a partial response, then psychotherapy, support, and education should be reevaluated. Choice of medication should also be reconsidered, with a consideration of antipsychotics. The National Cancer Institute’s Physician Data Query (PDQ®) provides information on cancer-related...

For patients diagnosed with adjustment disorder specifically, patients with moderate/severe disorder should receive medication and/or psychotherapy, while patients with mild disorder should receive psychotherapy only. For patients who receive medication, type of medication and the dosage should be adjusted as needed. Patients diagnosed with adjustment disorder that does not respond to treatment should have their treatment plan, support, and education re-evaluated and should also be evaluated for personality disorders.

Substance-Related and Addictive Disorders

Substance abuse and addiction are rare among patients with cancer who do not have a history of active abuse or addiction to opioids, alcohol, tobacco, cannabis, caffeine, or other supplements or prescription drugs. Substance use disorder developing during the course of the treatment may be due to insufficient symptom control and can be treated by improving symptom control. Alcohol and recreational drug use should be evaluated in patients with signs and symptoms of depressive disorders, bipolar and related disorders, and anxiety disorders, as substance use may exacerbate symptoms of these disorders. Safety concerns, as well as the patient’s decision-making ability and family and home environment, should be evaluated. The NCCN Guidelines for Adult Cancer Pain (available at www.NCCN.org) provide information on prescription, titration, maintenance, and safety of opioids. For patients who use tobacco, see the NCCN Guidelines for Smoking Cessation (available at www.NCCN.org).

In patients with a history of substance use disorder, its impact on cancer treatment should be assessed. Patients with a history of substance use disorder should also be monitored for signs and symptoms of relapse. Referral should be considered for risk reduction, substance use disorder management, or specialized treatment programs as needed. For patients with current substance dependence issues, symptoms should be treated and they should enter an appropriate substance use disorder treatment program. Patients who are intoxicated may require acute management in a medical setting, especially if there is a history of complicated withdrawal. Risk reduction strategies should be discussed with all patients who have either a current substance use disorder or a history of a substance use disorder.

Following the appropriate treatment/management program, patients should be provided with psychoeducation with or without psychotherapy and with or without medication. CBT may be effective for substance use disorder, though a meta-analysis of 53 studies showed only a small effect (Hedges’ g = 0.15, P < .005).314 Studies evaluating the efficacy of CBT for substance use disorder in patients with cancer are lacking. Referral can also be made to specialized maintenance programs, and strategies to prevent future abuse can be discussed.

Personality Disorders

Patients with cancer may have a pre-existing personality disorder, which can be exacerbated by the stress of cancer and its treatment.315 When a personality disorder is suspected, the patient should be evaluated by a mental health professional, and safety, home situation, and decision-making capacity should be assessed. Referral to psychiatry should be considered. If possible, any medication or other factors that could be aggravating the condition should be modified. A coordinated behavioral, psychological, and medical treatment plan, with or without medication, should be developed with the health care team.
Social Work and Counseling Services

Social work and counseling interventions are recommended when a patient has a psychosocial or practical problem. Practical problems, which may be addressed by case managers and patient navigators, are illness-related concerns; basic needs (eg, housing, food, financial/insurance concerns, help with activities of daily living, transportation); employment, school, or career concerns; cultural or language issues; and family/caregiver availability. The guidelines outline interventions that vary according to the severity of the problem.

Common psychosocial problems are adjustment to illness; family conflicts and social isolation; difficulties in treatment decision-making; quality-of-life issues; difficulties with transitions in care; absent or unclear advance directive or other concerns about advance directives; domestic abuse and neglect; poor coping or communication skills; concerns about functional changes (eg, body image, sexual health); depressive symptoms and/or suicidal ideation; fears, nervousness, and worry; and issues pertaining to end of life and bereavement (including cultural and caregiver concerns).

Social work and counseling interventions for psychosocial problems are described in the Guidelines. Social workers intervene in mild psychosocial problems by using patient and family education, support groups, and/or sexual health or grief counseling and by suggesting available local resources. Social workers can also help foster healthy coping strategies, such as problem solving, cognitive restructuring, and emotional regulation. For moderate to severe psychosocial problems, counseling and psychotherapy are used (including sexual health and grief counseling); community resources are mobilized; problem solving is taught; and advocacy, education, and protective services are made available.

Spiritual and Chaplaincy Care

Religiousness and spirituality are positively associated with mental health in patients with cancer, and attendance at religious services is associated with lower cancer-related mortality. Many patients use their religious and spiritual resources to cope with illness, and many cite prayer as a major help. In addition, the diagnosis of cancer can cause an existential crisis, making spiritual support of critical importance. Balboni et al surveyed 230 patients with advanced cancer treated at multiple institutions who had failed to respond to first-line chemotherapy. The majority of patients (88%) considered religion as somewhat or very important. Nearly half of the patients (47%) reported receiving very minimal or no support at all from their religious community, and 72% reported receiving little or no support from their medical system. Importantly, patients receiving spiritual support reported a higher quality of life. Religiousness and spiritual support have also been associated with improved satisfaction with medical care. Astrow et al found that 73% of patients with cancer had spiritual needs, and that patients whose spiritual needs were not met reported lower quality of care and lower satisfaction with their care. A multi-institution study of 75 patients with cancer and 339 oncologists and nurses (the Religion and Spirituality in Cancer Care Study) found that spiritual care had a positive effect on patient-provider relationships and the emotional well-being of patients. However, a survey conducted in 2006 through 2009 found that most patients with advanced cancer never receive spiritual care from their oncology team. Spiritual needs may include searching for the meaning and purpose of life; searching for the meaning in experiencing a disease like cancer; being connected to others, a deity, and nature; maintaining access to religious/spiritual practices; spiritual well-being; talking about death and dying; making the most of one’s own life; and being independent and treated like a “normal person.”
A meta-analysis including 12 studies with 1878 patients showed that spiritual interventions improve quality of life ($d = 0.50$; 95% CI, 0.20–0.79), but the effect was small at 3- to 6-month follow-up ($d = 0.14$; 95% CI, -0.08–0.35). Another meta-analysis including 10 RCTs with 1239 patients also showed that spiritual interventions may improve quality of life, as well as depression and anxiety. However, the included studies were varied in their design, limiting the study conclusions. A meta-analysis including 24 studies showed that existential interventions positively affected existential well-being, quality of life, hope, and self-efficacy, though results were moderated by intervention characteristics (eg, therapist’s professional background, intervention setting).

The panel has included chaplaincy care as part of psychosocial services. All patients should be referred to a chaplaincy professional when their problems are spiritual or religious in nature or when they request it. Guided by the Religious and Spiritual Struggles Scale and the Existential Concerns Questionnaire, the panel identified issues that should be included as part of evaluation by a chaplain: interpersonal conflict regarding spiritual/religious beliefs and practices; concerns with lack of meaning and purpose; struggles with morality and values; doubts about beliefs; perceptions of being attacked by evil; preoccupation about religiosity; issues of forgiveness; concerns about one’s relationship with the sacred; concerns about death, dying, and the afterlife; grief and loss; feeling worthless or like a burden; loneliness; conflict between religious beliefs and treatment options; and ritual needs.

The panel has identified interventions that may be carried out based on this assessment. These interventions, which are based on recommendations by Spiritual Health Victoria, include spiritual/existential counseling, education, and rituals; meditation and/or prayer; referral to appropriate spiritual/existential community resources; and referral to other health care professionals (eg, palliative care, mental health professional) as needed.

The following guidelines on religion and spirituality in cancer care may also be useful for clinicians and patients:

- National Consensus Project Clinical Practice Guidelines for Quality Palliative Care, Fourth Edition, 2018. These guidelines provide a framework to acknowledge the patient’s religious and spiritual needs in a clinical setting. Spiritual, religious, and existential aspects of care are included as 1 of the 8 clinical practice domains.

- The National Cancer Institute’s comprehensive cancer information database (PDQ®) has information on “Spirituality in Cancer Care” for patients and for health care professionals.

Oncologist Burnout

The stress and demands of treating patients with cancer and making life and death decisions daily often cause psychologic distress for oncologists. This distress can in turn cause depression, anxiety, and fatigue. It can also cause moral distress, compassion fatigue, and/or burnout. Burnout, characterized by a lack of enthusiasm for work, feelings of cynicism, and a low sense of personal accomplishment with work, occurs in as many as 28% to 45% of oncologists. Burnout can affect patient care, physician-patient relationships, and personal relationships and can lead to substance use disorder and even suicide. Strategies for avoiding and reducing burnout include training in self-care, personal wellness, and mindful meditation, and behavioral change by medical schools, residency programs, hospitals, and private practices. Organizational strategies...
can also create a culture that is less stressful and less conducive to oncologist burnout.

**Summary**

Psychosocial care is an integral component of the clinical management of patients with cancer. The CoC’s accreditation standards include distress screening for all patients and referral for psychosocial care as needed. Screening for and treating distress in cancer benefits patients, their families/caregivers, and staff and helps improve the efficiency of clinic operations. For patients with cancer, integration of mental health and medical services is critically important. Spirituality and religion also play an important role in coping with the diagnosis and the illness for many patients with cancer.

The NCCN Guidelines for Distress Management recommend that each new patient be rapidly evaluated in the office or clinic waiting room for evidence of distress using the DT and Problem List as an initial global screen. A score of 4 or greater on the DT should trigger further evaluation by the oncologist or nurse and referral to an appropriate resource, if needed. The choice of which supportive care service is needed is dependent on the problem areas specified on the Problem List. Patients with practical and psychosocial problems should be referred to social work and counseling services; those with emotional or psychological problems should be referred to mental health professionals; and spiritual concerns should be referred to chaplaincy care. Physical concerns may be best managed by the medical team.

Education of patients and families is equally important to encourage them to recognize that control of distress is an integral part of their total cancer care. The patient version of the NCCN Guidelines for Distress Management is a useful tool to accomplish this (available at [www.NCCN.org](http://www.NCCN.org)).
NCCN Guidelines Version 2.2020
Distress Management

References


Distress Management


80. Mitchell AJ. Screening for cancer-related distress: when is implementation successful and when is it unsuccessful? Acta Oncol


190. Rollnick S, Miller WR. What is motivational interviewing? Behav Cogn Psychother 1995;23:325-334. Available at: https://www.cambridge.org/core/article/what-is-motivational-interviewing/F7E8B9E777291290E6DF0FDE37999C8D.


199. Brandao T, Schulz MS, Matos PM. Psychological intervention with couples coping with breast cancer: a systematic review. Psychol Health


231. Robinson S, Kissane DW, Brooker J, Burney S. A systematic review of the demoralization syndrome in individuals with progressive disease


246. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit


